Metastatic Breast Cancer (DBCOND0030200)

Identifiers

Synonyms

Breast Cancer Metastatic Cancer / Metastatic (Stage IV) Breast Cancer / Advanced/Metastatic Breast Cancer / Stage IV (Metastatic) Breast Cancer / Metastatic Breast Cancers / Breast cancer metastatic / Metastatic breast cancer / Carcinoma breast stage IV / Breast carcinoma NOS stage IV / Breast carcinoma stage IV / Breast cancer stage IV / Breast cancer NOS stage IV

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Anastrozole	A competitive, selective, non-steroidal aromatase inhibitor used as adjuvant therapy for the treatment of hormone receptor-positive breast cancer in postmenopausal women.	Aromatasetarget ATP-dependent translocase ABCB1transporter Cytochrome P450 3A4enzyme Cytochrome P450 3A5enzyme Cytochrome P450 2C8enzyme UDP-glucuronosyltransferase 1A4enzyme UDP-glucuronosyltransferase 1A3enzyme UDP-glucuronosyltransferase 2B7enzyme Cytochrome P450 1A2enzyme Cytochrome P450 2C9enzyme
Bevacizumab	A monoclonal anti-vascular endothelial growth factor antibody used in combination with antineoplastic agents for the treatment of many types of cancer.	Vascular endothelial growth factor A, long formtarget Complement C1q subcomponent subunit Atarget Complement C1q subcomponent subunit Btarget Complement C1q subcomponent subunit Ctarget Low affinity immunoglobulin gamma Fc region receptor III-Atarget Low affinity immunoglobulin gamma Fc region receptor II-atarget Low affinity immunoglobulin gamma Fc region receptor II-btarget Low affinity immunoglobulin gamma Fc region receptor II-ctarget High affinity immunoglobulin gamma Fc receptor Itarget
Carboplatin	A alkylating agent used to treat advanced ovarian cancer.	DNAtarget High affinity copper uptake protein 1transporter Protein SLC31A2transporter Xanthine dehydrogenase/oxidaseenzyme Myeloperoxidaseenzyme Glutathione S-transferase theta-1enzyme Metallothionein-1Aenzyme Metallothionein-2enzyme Superoxide dismutase [Cu-Zn]enzyme Glutathione S-transferase Penzyme Glutathione S-transferase Mu 1enzyme NAD(P)H dehydrogenase [quinone] 1enzyme Copper-transporting ATPase 1transporter Copper-transporting ATPase 2transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter ATP-binding cassette sub-family C member 2transporter
Conjugated estrogens	A mixture of estrogens used in estrogen replacement therapy for menopause and hypoestrogenism, used in the treatment of various malignancies, and used in the treatment of postmenopausal osteoporosis.	Estrogen receptortarget Cytochrome P450 3A4enzyme Cytochrome P450 1A2enzyme Catechol O-methyltransferaseenzyme ATP-binding cassette sub-family C member 3transporter ATP-binding cassette sub-family C member 4transporter Multidrug resistance-associated protein 1transporter Solute carrier organic anion transporter family member 1A2transporter Hepatic sodium/bile acid cotransportertransporter Solute carrier family 22 member 10transporter Organic anion transporter 3transporter Solute carrier organic anion transporter family member 1C1transporter Solute carrier organic anion transporter family member 1B1transporter Solute carrier organic anion transporter family member 2B1transporter ATP-dependent translocase ABCB1transporter Solute carrier family 22 member 6transporter Organic solute transporter subunit alphatransporter Organic solute transporter subunit betatransporter ATP-binding cassette sub-family C member 2transporter Solute carrier organic anion transporter family member 4A1transporter ATP-binding cassette sub-family C member 11transporter Solute carrier organic anion transporter family member 1B3transporter Solute carrier family 22 member 11transporter Solute carrier organic anion transporter family member 3A1transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Thyroxine-binding globulincarrier Sex hormone-binding globulincarrier Albumincarrier Estrogen receptor betatarget
Dexrazoxane	A cytoprotective drug used to prevent and improve cardiomyopathy associated with doxorubicin treatment for metastatic breast cancer.	DNA topoisomerase 2-alphatarget DNA topoisomerase 2-betatarget
Docetaxel	A taxoid antineoplastic agent used in the treatment of various cancers, such as locally advanced or metastatic breast cancer, metastatic prostate cancer, gastric adenocarcinoma, and head and neck cancer.	Apoptosis regulator Bcl-2target Tubulin beta-1 chaintarget Cytochrome P450 3A4enzyme Cytochrome P450 3A5enzyme Cytochrome P450 3A7enzyme ATP-dependent translocase ABCB1transporter ATP-binding cassette sub-family C member 10transporter Cytochrome P450 1B1enzyme Microtubule-associated protein 2target Microtubule-associated protein 4target Microtubule-associated protein tautarget Solute carrier organic anion transporter family member 1B3transporter Solute carrier family 22 member 7transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter ATP-binding cassette sub-family C member 2transporter Multidrug resistance-associated protein 1transporter Nuclear receptor subfamily 1 group I member 2target
Doxorubicin	A medication used to treat various cancers, including AIDS-associated Kaposi's Sarcoma and metastatic cancers.	DNA topoisomerase 2-alphatarget DNAtarget Cytochrome P450 3A4enzyme Cytochrome P450 2D6enzyme Cytochrome P450 2B6enzyme ATP-dependent translocase ABCB1transporter ATP-binding cassette sub-family C member 3transporter ATP-binding cassette sub-family C member 6transporter Multidrug resistance-associated protein 1transporter ATP-binding cassette sub-family C member 10transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Bile salt export pumptransporter Solute carrier family 22 member 16transporter Mitochondrial potassium channel ATP-binding subunittransporter Cytochrome P450 1B1enzyme Carbonyl reductase [NADPH] 1enzyme Carbonyl reductase [NADPH] 3enzyme Aldo-keto reductase family 1 member A1enzyme Aldo-keto reductase family 1 member C3enzyme NAD(P)H dehydrogenase [quinone] 1enzyme Xanthine dehydrogenase/oxidaseenzyme Nitric oxide synthase 3enzyme Nitric oxide synthase, inducibleenzyme Nitric oxide synthase 1enzyme NADH dehydrogenase [ubiquinone] iron-sulfur protein 2, mitochondrialenzyme NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrialenzyme NADH dehydrogenase [ubiquinone] iron-sulfur protein 7, mitochondrialenzyme NADPH--cytochrome P450 reductaseenzyme RalA-binding protein 1transporter ATP-binding cassette sub-family C member 2transporter Albumincarrier Nucleolar and coiled-body phosphoprotein 1target DNA topoisomerase 1target DNA topoisomerase 2-betatarget Aldo-keto reductase family 1 member B1enzyme Aldo-keto reductase family 1 member B10enzyme Aldo-keto reductase family 1 member C4enzyme Telomerase reverse transcriptasetarget
Elacestrant	An estrogen receptor antagonist used to treat ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.	Estrogen receptortarget Cytochrome P450 3A4enzyme Cytochrome P450 2A6enzyme Cytochrome P450 2C9enzyme Solute carrier organic anion transporter family member 2B1transporter ATP-dependent translocase ABCB1transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter
Esterified estrogens	A female hormone used to treat conditions related to estrogen deficiency and moderate to severe vasomotor menopausal symptoms in women.	Cytochrome P450 3A4enzyme Thyroxine-binding globulincarrier
Estradiol	An estrogenic steroid used to treat vasomotor symptoms of vulvar and vaginal atrophy in menopause, hypoestrogenism, prevention of postmenopausal osteoporosis, treatment of breast cancer, and advanced androgen-dependent carcinoma of the prostate.	Estrogen receptortarget Nuclear receptor subfamily 1 group I member 2target Sex hormone-binding globulincarrier Estrogen receptor betatarget Cytochrome P450 1A2enzyme UDP-glucuronosyltransferase 1A1enzyme Albumincarrier Fatty acid-binding protein, intestinalcarrier Cytochrome P450 3A4enzyme Cytochrome P450 3A5enzyme Cytochrome P450 3A7enzyme Solute carrier family 22 member 2transporter Solute carrier family 22 member 3transporter ATP-binding cassette sub-family C member 10transporter Solute carrier family 22 member 11transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Solute carrier organic anion transporter family member 1B1transporter ATP-dependent translocase ABCB1transporter Cytochrome P450 1A1enzyme Cytochrome P450 1B1enzyme Cytochrome P450 2C19enzyme Cytochrome P450 2C8enzyme Cytochrome P450 2C9enzyme Organic anion transporter 3transporter Solute carrier organic anion transporter family member 1B3transporter Solute carrier organic anion transporter family member 1C1transporter Neuronal acetylcholine receptor subunit alpha-4target G-protein coupled estrogen receptor 1target ATP synthase subunit atarget Beclin-1target UDP-glucuronosyltransferase 2B15enzyme Catechol O-methyltransferaseenzyme UDP-glucuronosyltransferases (UGTs)enzyme Aromataseenzyme
Gemcitabine	A nucleoside metabolic inhibitor used as adjunct therapy in the treatment of certain types of ovarian cancer, non-small cell lung carcinoma, metastatic breast cancer, and as a single agent for pancreatic cancer.	Ribonucleoside-diphosphate reductase large subunittarget UMP-CMP kinasetarget Thymidylate synthasetarget Cytidine deaminaseenzyme Deoxycytidine kinaseenzyme ATP-dependent translocase ABCB1transporter ATP-binding cassette sub-family C member 10transporter Equilibrative nucleoside transporter 1transporter DNAtarget Sodium/nucleoside cotransporter 1transporter Equilibrative nucleoside transporter 2transporter Solute carrier family 28 member 3transporter Thymidine kinase 2, mitochondrialenzyme UMP-CMP kinaseenzyme Nucleoside diphosphate kinase Aenzyme Ribonucleoside-diphosphate reductase subunit M2target
Hyaluronidase (human recombinant)	An enzyme used to improve the absorption and dispersion of parenterally administered fluids, drugs, and contrast agents.	Hyaluronic acidtarget Transforming growth factor beta-1 proproteintarget
Ixabepilone	A microtubule inhibitor administered in combination with capecitabine or alone in the treatment of metastatic or locally advanced breast cancer that has shown inadequate response to taxanes and anthracyclines.	Tubulin beta-3 chaintarget Cytochrome P450 3A4enzyme ATP-dependent translocase ABCB1transporter
Lapatinib	An antineoplastic agent and tyrosine kinase inhibitor used for the treatment of advanced or metastatic HER-positive breast cancer in patients who received prior chemotherapeutic treatments.	Epidermal growth factor receptortarget Receptor tyrosine-protein kinase erbB-2target Cytochrome P450 3A4enzyme Cytochrome P450 2C8enzyme ATP-dependent translocase ABCB1transporter Antigen peptide transporter 1transporter Cytochrome P450 3A5enzyme Cytochrome P450 2C19enzyme Eukaryotic elongation factor 2 kinasetarget
Methyltestosterone	A synthetic anabolic steroid used for the replacement therapy in conditions associated with testosterone deficiencies in males, such as hypogonadism, and treatment of advancing inoperable metastatic breast cancer in females.	Cytochrome P450 2B6enzyme Cytochrome P450 3A4enzyme Androgen receptortarget Solute carrier organic anion transporter family member 1A2transporter Organic anion transporter 3transporter Albumincarrier Sex hormone-binding globulincarrier Estrogen receptortarget Aromataseenzyme
Mitoxantrone	A chemotherapeutic agent used for the treatment of secondary progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis.	DNA topoisomerase 2-alphatarget Cytochrome P450 2E1enzyme ATP-dependent translocase ABCB1transporter Multidrug resistance-associated protein 1transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter DNAtarget Cytochrome P450 1B1enzyme Cytochrome P450 3A4enzyme DNA topoisomerase 2-betatarget
Olaparib	A poly (ADP-ribose) polymerase (PARP) inhibitor used to treat ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer.	Poly [ADP-ribose] polymerase 1target Cytochrome P450 3A4enzyme Cytochrome P450 2B6enzyme Poly [ADP-ribose] polymerase 2target Protein mono-ADP-ribosyltransferase PARP3target Cytochrome P450 3A5enzyme ATP-dependent translocase ABCB1transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Aldo-keto reductase family 1 member C3target UDP-glucuronosyltransferase 1A1enzyme Albumincarrier Alpha-1-acid glycoprotein 1carrier
Paclitaxel	A taxoid chemotherapeutic agent used as first-line and subsequent therapy for the treatment of advanced carcinoma of the ovary, and other various cancers including breast and lung cancer.	Apoptosis regulator Bcl-2target Tubulin beta-1 chaintarget Cytochrome P450 2C8enzyme Cytochrome P450 3A4enzyme Cytochrome P450 3A5enzyme Cytochrome P450 3A7enzyme Bile salt export pumptransporter ATP-dependent translocase ABCB1transporter Multidrug resistance-associated protein 1transporter ATP-binding cassette sub-family C member 10transporter Aromataseenzyme Cytochrome P450 1B1enzyme Solute carrier organic anion transporter family member 1B3transporter Nuclear receptor subfamily 1 group I member 2target Microtubule-associated protein 4target Microtubule-associated protein 2target Microtubule-associated protein tautarget ATP-binding cassette sub-family C member 2transporter
Palbociclib	An endocrine-based chemotherapeutic agent used in combination with other antineoplastic agents to treat HER2-negative and HR-positive advanced or metastatic breast cancer.	Cyclin-dependent kinase 4target Cyclin-dependent kinase 6target Cytochrome P450 3A4enzyme Sulfotransferase 2A1enzyme ATP-dependent translocase ABCB1transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Albumincarrier Solute carrier family 22 member 1transporter
Pertuzumab	An antineoplastic agent used in the treatment of HER2-positive metastatic breast cancer in combination with other antineoplastic agents.	Receptor tyrosine-protein kinase erbB-2target
Ribociclib	A kinase inhibitor used to treat HR+, HER2- advanced or metastatic breast cancer.	Cyclin-dependent kinase 4target Cyclin-dependent kinase 6target Cytochrome P450 3A4enzyme
Talazoparib	A poly-ADP ribose polymerase inhibitor used to treat HER2-, BRCA mutated locally advanced or metastatic breast cancer and HRR gene-mutated metastatic castration-resistant prostate cancer.	Poly [ADP-ribose] polymerase 1target Poly [ADP-ribose] polymerase 2target ATP-dependent translocase ABCB1transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter
Toremifene	A first generation nonsteroidal selective estrogen receptor modulator used to treat certain breast cancers.	Estrogen receptortarget Cytochrome P450 3A4enzyme ATP-dependent translocase ABCB1transporter Cytochrome P450 1A1enzyme Sex hormone-binding globulintarget
Trastuzumab	A monoclonal anti-human epidermal growth factor receptor 2 protein antibody used to treat HER2-positive breast, gastroesophageal, and gastric cancers.	Receptor tyrosine-protein kinase erbB-2target
Vinorelbine	A vinca alkaloid used in the treatment of metastatic non-small cell lung carcinoma (NSLC) and in conjunction with other drugs in locally advanced NSCLC.	Tubulin beta chaintarget Cytochrome P450 3A4enzyme Cytochrome P450 2D6enzyme

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT01048918	Characterization of Circulating Tumor Cells (CTC-s) in Patients With Locally Advanced or Metastatic Stage IV Breast Cancer	No drug interventions	Not Available	Not Available	completed
NCT00662025	Study Of Sunitinib With Capecitabine In Breast Cancer	Capecitabine Sunitinib	treatment	2	completed
NCT02338167	Praegnant Breast Cancer: Early/Advanced/Metastatic	No drug interventions	Not Available	Not Available	recruiting
NCT04901299	Fulvestrant + Neratinib In Breast Cancer	Fulvestrant Neratinib	treatment	2	withdrawn
NCT00140140	A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer	Filgrastim Paclitaxel Trastuzumab Vinorelbine	treatment	1 / 2	terminated
NCT06585969	A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-negative Metastatic Breast Cancer	Abemaciclib Ribociclib Trastuzumab deruxtecan	treatment	3	not_yet_recruiting
NCT06619704	Observational Retrospective Study to Assess the Use of Ribociclib in Patients With HR+, HER2- Metastatic Breast Cancer Treated With Chemotherapy	No drug interventions	Not Available	Not Available	completed
NCT02000622	Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.	Olaparib	treatment	3	active_not_recruiting
NCT02390427	Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer	Paclitaxel Pertuzumab Taselisib Trastuzumab Trastuzumab emtansine	treatment	1	completed
NCT02965755	Personalized Molecular Profiling in Cancer Treatment at Johns Hopkins	No drug interventions	treatment	Not Available	active_not_recruiting
NCT03079011	PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection	Anastrozole Exemestane Fulvestrant Letrozole Palbociclib	treatment	3	active_not_recruiting
NCT03355157	A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study).	Capecitabine Epirubicin Exemestane Fulvestrant Letrozole Paclitaxel Palbociclib Tamoxifen Vinorelbine	treatment	4	completed
NCT03808337	Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease	No drug interventions	treatment	2	recruiting
NCT04538742	A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer	Durvalumab Paclitaxel Pertuzumab Trastuzumab deruxtecan Tucatinib	treatment	1 / 2	active_not_recruiting
NCT05508906	Phase 1b Combo w/ Ribociclib, Alpelisib, or Everolimus	Alpelisib Everolimus Palazestrant Ribociclib	treatment	1	recruiting
NCT05696626	Evaluation of Lasofoxifene Combined with Abemaciclib Compared with Fulvestrant Combined with Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer with an ESR1 Mutation	Abemaciclib Fulvestrant Lasofoxifene	treatment	3	recruiting
NCT05721248	STOP-HER2: Stopping Trastuzumab in HER2+ MBC	No drug interventions	treatment	2	recruiting
NCT05868226	PRE-I-SPY Phase I/Ib Oncology Platform Program	Evorpacept Trastuzumab deruxtecan Tucatinib Zanidatamab	treatment	1	recruiting
NCT05894239	A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer	Hyaluronidase (human recombinant) Inavolisib Pertuzumab Trastuzumab	treatment	3	recruiting
NCT05977036	BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer	No drug interventions	treatment	Not Available	recruiting
NCT06120283	BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors	Fulvestrant Letrozole	treatment	1	recruiting
NCT06157892	A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors	Disitamab vedotin Tucatinib	treatment	1 / 2	recruiting
NCT06246968	A Study of Pembrolizumab and Cryoablation in People with Breast Cancer	Pembrolizumab	treatment	1	recruiting
NCT06343987	The FEMA Study: Feasibility of Exercise in Patients with Metastatic Breast Cancer and Adiposity	No drug interventions	treatment	Not Available	recruiting
NCT06386263	HER-TEMPO - Real World Treatment-related Outcomes on T-DXd in Canada	Trastuzumab deruxtecan	Not Available	Not Available	recruiting
NCT06409390	Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer	Abemaciclib Capecitabine Cyclophosphamide Docetaxel Fulvestrant Ribociclib Sacituzumab govitecan Trastuzumab deruxtecan	treatment	0	recruiting
NCT06625775	Dose Escalation and Expansion of BBO-10203 in Advanced Solid Tumors (BREAKER-101)	Trastuzumab	treatment	1	not_yet_recruiting
NCT04660435	To Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer	No drug interventions	Not Available	Not Available	recruiting
NCT04699630	A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer	No drug interventions	treatment	2	recruiting
NCT04796324	Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.	Ixabepilone	treatment	2	recruiting
NCT05002868	Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors	No drug interventions	treatment	1	completed
NCT05216432	First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, As a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer	Fulvestrant Palbociclib RLY-2608 Ribociclib	treatment	1	recruiting
NCT05349227	Comprehensive Outcomes for After Cancer Health	No drug interventions	supportive_care	Not Available	recruiting
NCT05383196	Onvansertib + Paclitaxel in TNBC	Onvansertib Paclitaxel	treatment	1 / 2	recruiting
NCT05596409	ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study	Elacestrant	treatment	2	recruiting
NCT06607601	CARE Initiative: Real-world Emulation of the PALOMA-2 Trial	Letrozole Palbociclib	Not Available	Not Available	completed
NCT05708703	Assessing the Time Demands of Cancer	No drug interventions	Not Available	Not Available	active_not_recruiting
NCT05735080	Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients with Advanced Cancer	Fulvestrant	treatment	1 / 2	recruiting
NCT05744375	Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab	Trastuzumab deruxtecan	treatment	2	recruiting
NCT05810870	PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin	CH-5132799 Eribulin	treatment	2	recruiting
NCT05846789	Phase II Trial of Carboplatin +/- Tocilizumab for Metastatic Triple Negative and ER-low Breast Cancers	Carboplatin Tocilizumab	treatment	2	recruiting
NCT05865990	HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease	No drug interventions	treatment	2	active_not_recruiting
NCT06016738	OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer	Anastrozole Exemestane Fulvestrant Letrozole Palazestrant	treatment	3	recruiting
NCT06048718	T-DXd Therapy for HER2-low Breast Cancer Patients With Brain Metastases	Trastuzumab deruxtecan	treatment	2	recruiting
NCT06099769	A Study of Enzalutamide, Enzalutamide in Combination with Mifepristone, or Chemotherapy in People with Metastatic Breast Cancer	Enzalutamide Mifepristone	treatment	2	recruiting
NCT06105684	Phase II Single Arm Trial of Low Dose Capecitabine in Patients With Advanced Breast Cancer	Capecitabine	treatment	2	not_yet_recruiting
NCT06324357	Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib in Combination With Trastuzumab Deruxtecan or With Trastuzumab Emtansine and to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread	Trastuzumab deruxtecan Trastuzumab emtansine Zongertinib	treatment	1 / 2	recruiting
NCT06342037	NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial	Atezolizumab Ipilimumab Tiragolumab	treatment	2	recruiting
NCT06611891	Evaluation of Somatostatin Receptor Expression in PET 68Ga-DOTATOC in Patients Followed for Metastatic Breast Cancer	Dotatate gallium Ga-68	diagnostic	3	not_yet_recruiting
NCT06369831	HER2 Targeted Molecular Imaging in MBC Using 68Ga-ABS011	No drug interventions	diagnostic	2	recruiting
NCT06417801	Prevalence of Emerging Treatment-induced Mutations in Metastatic ER-positive Breast Cancer.	No drug interventions	Not Available	Not Available	recruiting
NCT06612814	PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer	Dalpiciclib Fluzoparib Fulvestrant	treatment	3	active_not_recruiting
NCT06590857	Trial of 225Ac-DOTATATE (RYZ101) Alone and with Pembrolizumab in Subjects with ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs	Pembrolizumab	treatment	1 / 2	recruiting
NCT06616987	Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Nagative Breast Cancer	Pegfilgrastim Sacituzumab govitecan	treatment	2	not_yet_recruiting
NCT06598046	A Single-arm, Prospective Phase Ⅱ Clinical Study of Utidelone Combined with Capecitabine in the Treatment of Active Brain Metastasis of TNBC	Capecitabine Utidelone	treatment	2	recruiting
NCT00890903	Non-Interventional Study With Vinorelbine ORAL in Advanced Non-Small Cell Lung Carcinoma(NSCLC) and Metastatic Breast Cancer (MBC)	No drug interventions	Not Available	Not Available	completed
NCT05609903	Atezolizumab With Nab-paclitaxel for Patients With Triple-negative Stage IV Breast Cancer	Atezolizumab Paclitaxel	Not Available	Not Available	completed
NCT00915603	Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer	Bevacizumab Everolimus Paclitaxel	treatment	2	completed
NCT02102490	A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread	Abemaciclib	treatment	2	completed
NCT03184090	Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ mBC	Palbociclib	treatment	2	completed
NCT06154590	Anastrozole Adjuvant Trial - Study of Anastrozole Compared to NOLVADEX (Tamoxifen Citrate) for Adjuvant Treatment of Early Breast Cancer Clinical Studies), Adjunct Cytotoxic Chemotherapy and Malignant Joint Tumor	Fluorouracil Melphalan Tamoxifen	Not Available	Not Available	not_yet_recruiting
NCT04095390	A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer	Capecitabine Dalpiciclib Letrozole Pyrotinib	treatment	2	unknown_status
NCT02666690	Study of the Intra-patient Variability of the Quantitative Parameters of Tumor Perfusion Evaluated With Ultrasound Contrast	No drug interventions	Not Available	Not Available	completed
NCT04720664	Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer	No drug interventions	treatment	2	terminated
NCT04646564	Radiotherapy for Extracranial Oligometastatic Breast Cancer	No drug interventions	treatment	3	recruiting
NCT00633464	Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative Locally Advanced Non-resectable and/or Metastatic Breast Cancer	Cetuximab Ixabepilone	treatment	2	completed
NCT03975621	Nurse AMIE: Addressing Metastatic Individuals Everyday	No drug interventions	supportive_care	Not Available	completed
NCT01045421	Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies	Alisertib	treatment	1 / 2	completed
NCT06489821	STereotactic Body Radiotherapy (SBRT) for Oligoprogressive Breast Cancer	No drug interventions	treatment	Not Available	not_yet_recruiting
NCT01240421	An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory	Eribulin	Not Available	Not Available	approved_for_marketing
NCT01231802	Study of Eniluracil + 5-Fluorouracil (5-FU) + Leucovorin Versus Capecitabine in Metastatic Breast Cancer	Capecitabine Eniluracil Fluorouracil Leucovorin	treatment	2	unknown_status
NCT01837602	cMet CAR RNA T Cells Targeting Breast Cancer	No drug interventions	treatment	1	completed
NCT00334802	Combination Chemotherapy of Gemcitabine and Paclitaxel for Metastatic Breast Cancer	Gemcitabine Paclitaxel	treatment	2	completed
NCT04579484	Determinants of Acquired Endocrine Resistance in Metastatic Breast Cancer: A Pilot Study	No drug interventions	Not Available	Not Available	unknown_status
NCT05524584	Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer	Abemaciclib Anastrozole Fulvestrant	treatment	2	recruiting
NCT05963984	A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants	Fulvestrant Samuraciclib	treatment	2	recruiting
NCT04134884	Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer	Talazoparib	treatment	1	completed
NCT04683679	A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer	Olaparib Pembrolizumab	treatment	2	recruiting
NCT05420779	A Study to Evaluate the Efficacy and Safety of TSL-1502 Capsules in Breast Cancer Patients With Germline BRCA Mutations	No drug interventions	treatment	2	recruiting
NCT03501979	Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD	Capecitabine Trastuzumab Tucatinib	treatment	2	active_not_recruiting
NCT04478279	A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors	ST-101 Temozolomide	treatment	1 / 2	active_not_recruiting
NCT02101879	Cardiotoxicity in Metastatic Her 2 Positive Patients Treated With Trastuzumab ,Pertuzumab and Taxanes	No drug interventions	Not Available	Not Available	unknown_status
NCT04986579	Scalp Cooling in MBC	Eribulin Sacituzumab govitecan Trastuzumab deruxtecan	supportive_care	2	recruiting
NCT03147287	Palbociclib After CDK and Endocrine Therapy (PACE)	Avelumab Fulvestrant Palbociclib	treatment	2	active_not_recruiting
NCT02393287	Retroprospective Real Life Observatory of Eribulin	No drug interventions	Not Available	Not Available	completed
NCT03876587	Pyrotinib Combined With Docetaxel in the First-line Treatment of HER2-positive MBC	Docetaxel	treatment	2	unknown_status
NCT04669587	ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study)	Palbociclib	treatment	1 / 2	unknown_status
NCT04315233	Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics	Belinostat Ribociclib	treatment	1	recruiting
NCT04298333	Dose-finding Study of BP-C1 in Patients With Stage IV Breast Cancer	Platinum	supportive_care	1	completed
NCT06414733	Vaccine Therapy in Treating Patients With Metastatic Solid Tumors	No drug interventions	treatment	1	not_yet_recruiting
NCT04354233	A Physical Activity Program to Improve Quality of Life and Reduce Fatigue in Metastatic Breast Cancer	No drug interventions	supportive_care	Not Available	recruiting
NCT01725633	Aerobic Training in Metastatic Breast Cancer	No drug interventions	supportive_care	Not Available	completed
NCT00645333	Phase I/II Study of MK-0752 Followed by Docetaxel in Advanced or Metastatic Breast Cancer	Docetaxel MK-0752 Pegfilgrastim	treatment	1 / 2	completed
NCT04176354	Real-world Treatment Patterns and Effectiveness of Palbociclib and AI Therapy	Letrozole Palbociclib	Not Available	Not Available	completed
NCT05732051	Nicotinamide Riboside and Prevention of Cancer Therapy Related Cardiac Dysfunction in Breast Cancer Patients	No drug interventions	prevention	2	recruiting
NCT02524951	Safety and Tolerability of MSI-1436C in Metastatic Breast Cancer	Trodusquemine	treatment	1	terminated
NCT04042051	Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer	Copanlisib Trastuzumab emtansine	treatment	1	terminated
NCT01596751	Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer	Eribulin Pexidartinib	treatment	1 / 2	completed
NCT03045653	Efficacy of High Dose Tamoxifen to Advanced Hormone Receptor-High Expressed Breast Cancer	Tamoxifen	treatment	2	completed
NCT02322853	A Multicenter Trial Assessing the Efficacy and Safety of tamOxifen Plus LY2228820 in Advanced or Metastatic Breast Cancer Progressing on aromatasE Inhibitors	Ralimetinib Tamoxifen	treatment	2	terminated
NCT02723877	PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO)	Bimiralisib Eribulin	treatment	1 / 2	completed
NCT06023277	A Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of ConvitVax in Metastatic Breast Cancer	No drug interventions	treatment	1 / 2	not_yet_recruiting
NCT01360177	Radioactive Iodide (131I) Treatment of 124I PET/CT Detected Breast Cancers	No drug interventions	treatment	Not Available	withdrawn
NCT01978977	Maintenance Bevacizumab or Observation After Taxane Based First Line Chemotherapy In Metastatic Breast Cancer	No drug interventions	Not Available	Not Available	completed
NCT01730677	Lapatinib+Vinorelbine vs Vinorelbine HER2 Positive Metastatic Breast Cancer Progressed After Lapatinib/Trastuzumab	Lapatinib Vinorelbine	treatment	2	unknown_status
NCT02528747	A Survey of Breast Cancer Patients With Metastatic Bone Disease Receiving Oral Ibandronate	No drug interventions	Not Available	Not Available	completed
NCT05662345	ACT-MBC: A Study of Circulating Tumor Cells (CTCs) in Metastatic Breast Cancer (MBC)	No drug interventions	Not Available	Not Available	recruiting
NCT03824145	Every Day Counts: A Lifestyle Program for Women With Metastatic Breast Cancer	No drug interventions	supportive_care	Not Available	recruiting
NCT02188745	ER Reactivation Therapy for Breast Cancer	Anastrozole Estradiol Exemestane Letrozole	treatment	2	completed
NCT02632045	Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer	Fulvestrant Ribociclib	treatment	2	active_not_recruiting
NCT01361945	AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast Cancer	AUY922	treatment	1 / 2	withdrawn
NCT02338245	Study of ASLAN001 in Combination With Capecitabine in MBC That Has Failed on Prior Trastuzumab	Capecitabine Lapatinib Varlitinib	treatment	2	completed
NCT02392845	A Pilot Dose Escalation Trial of a Densified Chemotherapy Association of Docetaxel and Epirubicin Driven by Mathematical Modeling in Metastatic Breast Cancer Patients: The MODEL1 Study	Docetaxel Epirubicin	treatment	1	completed
NCT00911898	A Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers	MM-111	treatment	1	completed
NCT06062498	Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer	Abemaciclib Elacestrant Palbociclib Ribociclib	treatment	2	not_yet_recruiting
NCT00358098	Study to Determine the Utility of FES-PET and FDG-PET in the Prediction of Response to Hormone Therapy in Women With Estrogen Positive Metastatic Breast Cancer	No drug interventions	Not Available	Not Available	terminated
NCT04120298	Effects of Exercise in Patients With Metastatic Breast Cancer	No drug interventions	supportive_care	Not Available	active_not_recruiting
NCT01149798	A Combination of Abraxane and Cisplatin in Metastatic Breast Cancer	Cisplatin Paclitaxel	treatment	2	completed
NCT04167605	Evaluation of Prognostic Factors: From Breast Cancer to Bone Metastases	No drug interventions	Not Available	Not Available	recruiting
NCT04483505	Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer.	Fulvestrant Palbociclib Rogaratinib	other	1	completed
NCT03577197	Southeast Netherlands Advanced Metastatic Breast Cancer Registry	No drug interventions	Not Available	Not Available	recruiting
NCT03603197	BP-C1 in Short-term Treatment of Thai Patients With Metastatic Breast Cancer	Platinum	treatment	2	completed
NCT03789097	Vaccination With Flt3L, Radiation, and Poly-ICLC	CDX-301 Hiltonol Pembrolizumab	treatment	1 / 2	recruiting
NCT00480597	Gemcitabine/Vinorelbine Versus Gemcitabine/Cisplatin Versus Gemcitabine/Capecitabine in Metastatic Breast Cancer	Capecitabine Cisplatin Gemcitabine Vinorelbine	treatment	2	completed
NCT02137083	A Trial Comparing Docetaxel Plus Fulvestrant With Docetaxel in Metastatic Breast Cancer	Docetaxel Fulvestrant	treatment	2	completed
NCT02924883	A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy	Atezolizumab Trastuzumab emtansine	treatment	2	completed
NCT04603183	ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL	Abemaciclib Fulvestrant Letrozole Paclitaxel	treatment	2	active_not_recruiting
NCT04253561	Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients	Ipatasertib Pertuzumab Trastuzumab	treatment	1	recruiting
NCT02909361	Fulvestrant 500mg in Patients With Advanced Breast Cancer	Fulvestrant	Not Available	Not Available	unknown_status
NCT01120561	A Study of Trastuzumab-MCC-DM1 in Patients With HER2- Positive Locally Advanced or Metastatic Breast Cancer	Trastuzumab emtansine	Not Available	Not Available	no_longer_available
NCT00986661	A Study to Assess PV-10 Chemoablation of Cancer of the Liver	Rose bengal alpha-Pyrrolidinononanophenone	treatment	1	active_not_recruiting
NCT00517361	Phase II Study of Carboplatin and Bevacizumab (Avastin) for ER Neg, PR Neg, and HER2/Neu Neg Metastatic Breast Cancer	Bevacizumab Carboplatin	treatment	2	terminated
NCT06202261	A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer	Albumin human Capecitabine Eribulin Fulvestrant Gemcitabine Paclitaxel Vinorelbine	treatment	1 / 2	recruiting
NCT05559528	BRaziLian outcomE for metAStatic breasT Cancer	No drug interventions	Not Available	Not Available	recruiting
NCT03505528	An Early Phase Study of Abraxane Combined With Phenelzine Sulfate in Patients With Metastatic or Advanced Breast Cancer	Albumin human Paclitaxel Phenelzine	treatment	1	completed
NCT01240928	MK-2206+Endocrine Therapy in Patients With Hormone Receptor-Positive Breast Cancer	Exemestane Goserelin	treatment	1	withdrawn
NCT01733628	Evaluation of Hypertension as a Predictor of Efficacy Bevacizumab in Metastatic Breast Cancer and Colorectal Cancer	No drug interventions	Not Available	Not Available	completed
NCT02447328	A Single Arm, Tolerability and Safety Phase IV Study of Fulvestrant(Faslodex® ) as 2nd Line and Later Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer	Fulvestrant	other	4	completed
NCT06405828	Enhancing Access to Supportive Services for Women of Color With Metastatic Breast Cancer	No drug interventions	supportive_care	Not Available	recruiting
NCT06106711	The Impact of Adverse Events, Produced by Antibodies Conjugates, on Quality of Life in Patients With Metastatic Breast Cancer: Multicentric, Observational Study (EVA).	No drug interventions	Not Available	Not Available	not_yet_recruiting
NCT00679211	A Study of Trastuzumab-Mcc-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer	Trastuzumab emtansine	treatment	2	completed
NCT05065411	Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer	Abemaciclib Enobosarm Everolimus Exemestane Fulvestrant	treatment	3	terminated
NCT06439693	The SAPPHO Study: A Single-Arm, Phase II Study of Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer	Albumin human Docetaxel Hyaluronidase (human recombinant) Paclitaxel Pertuzumab Trastuzumab Trastuzumab deruxtecan Trastuzumab emtansine Tucatinib	treatment	2	not_yet_recruiting
NCT04165993	Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast Cancer	Anbenitamab Erfonrilimab	treatment	2	active_not_recruiting
NCT01322893	Enumeration and Molecular Characterization of Circulating Tumour Cells in Women With Metastatic Breast Cancer	No drug interventions	Not Available	Not Available	completed
NCT06110793	A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer	Fulvestrant Lenvatinib	treatment	1 / 2	recruiting
NCT01985893	Safety and Efficacy of Lapatinib Plus Trastuzumab or Lapatinib Plus Capecitabine in Metastatic Breast Cancer	Lapatinib Trastuzumab	treatment	2	withdrawn
NCT02594371	Ph3 Study To Determine Safety,Tolerability&Tumor Response Of Oraxol Compared To Taxol In Metastatic Breast Cancer	HM-30181 Paclitaxel	treatment	3	completed
NCT02632071	ACY-1215 + Nab-paclitaxel in Metastatic Breast Cancer	Paclitaxel Ricolinostat	treatment	1	completed
NCT00240071	Study of Avastin (Bevacizumab) to Reverse Acquired Estrogen Independence in Previously Hormone Responsive Metastatic Breast Ca.	Anastrozole Bevacizumab Exemestane Letrozole Tamoxifen	treatment	2	completed
NCT05574478	Metastatic Breast Cancer-Specific Prognostic Tool	No drug interventions	Not Available	Not Available	active_not_recruiting
NCT00614978	Lapatinib and Temozolomide for the Treatment of Progressive Brain Disease in HER-2 Positive Breast Cancer	Lapatinib Temozolomide	treatment	1	completed
NCT05302778	Eribulin as a Second-line Treatment in Triple-negative Advanced Breast Cancer	No drug interventions	Not Available	Not Available	recruiting
NCT01009788	ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer	Temozolomide Veliparib	treatment	2	active_not_recruiting
NCT04407988	Pyrotinib in Combination With Letrozole in Patients With HER2-Positive, ER-Positive Metastatic Breast Cancer	Letrozole Pyrotinib	treatment	2	unknown_status
NCT03507088	Study to Determine the Utility of FES-PET in the Prediction of Response to Fulvestrant in Women With Estrogen Positive Metastatic Breast Cancer	Fulvestrant	treatment	Not Available	completed
NCT00387907	Study of Larotaxel in Combination With Weekly Herceptin® in Patients With HER2 Positive Metastatic Breast Cancer	Larotaxel Trastuzumab	treatment	2	completed
NCT02028507	Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors	Capecitabine Exemestane Fulvestrant Palbociclib	treatment	3	completed
NCT04030507	Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer	No drug interventions	screening	Not Available	recruiting
NCT00270907	CT-2103 in Combination With Gemcitabine in Metastatic Breast Cancer	Gemcitabine Paclitaxel poliglumex	treatment	1	completed
NCT00148707	Study of Xyotax (CT-2103) in Patients With Metastatic Breast Cancer	Paclitaxel poliglumex	treatment	2	completed
NCT05207709	Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype	Fulvestrant Letrozole Paclitaxel Palbociclib Ribociclib Tislelizumab	treatment	3	recruiting
NCT01990209	Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)	Orteronel	treatment	2	completed
NCT02238509	Safety and QoL of Trastuzumab With Lapatinib or Chemiotherapy in MBC and HER2+ Patients Refractory to Anti HER2 Therapies	Lapatinib Trastuzumab	treatment	2	unknown_status
NCT01185509	Trastuzumab and Vinorelbine in Advanced Breast Cancer	Trastuzumab Vinorelbine	treatment	2	terminated
NCT01482156	Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors	Dactolisib Everolimus	treatment	1	completed
NCT04992156	Prediction of 18F-FES-PET/CT Parameters on Palbociclib Combined With ET	Palbociclib	Not Available	Not Available	completed
NCT03568656	Study to Evaluate CCS1477 in Advanced Tumours	Abiraterone Atezolizumab Darolutamide Enzalutamide Inobrodib Olaparib	treatment	1 / 2	recruiting
NCT00225056	Phase II Study of Capecitabine and Weekly Docetaxel Followed by Capecitabine Maintenance for Patients With Metastatic Breast Carcinoma	Capecitabine Docetaxel	treatment	2	terminated
NCT05206656	Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer	Anlotinib Eribulin	treatment	2	completed
NCT00624156	Expressive Writing and Adjustment to Metastatic Breast Cancer	No drug interventions	Not Available	Not Available	completed
NCT00903656	Lapatinib Plus Caelyx in Patients With Advanced Metastatic Breast Cancer Following Failure of Trastuzumab Therapy	Lapatinib	treatment	2	terminated
NCT00274456	Phase II Trial Comparing ABI-007 (Abraxane®, Nab®-Paclitaxel) to Taxotere in First Line Therapy of Patients With Stage IV Breast Cancer	Docetaxel Paclitaxel	treatment	2	completed
NCT02129556	Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast Cancer	Pembrolizumab Trastuzumab	treatment	1 / 2	completed
NCT06369285	A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer	Alisertib	treatment	2	not_yet_recruiting
NCT01654185	Dimethyldiguanide Combined With Aromatase Inhibitor (AI) in Metastatic Breast Cancer	Exemestane Letrozole	treatment	2	completed
NCT01044485	Lapatinib in Combination With Docetaxel in Patients With HER-2 Positive Advanced or Metastatic Breast Cancer	Docetaxel Lapatinib	treatment	1 / 2	completed
NCT03086785	Prospective, Multicenter, Observational Study of Apatinib Single or Combined Capecitabine for Treatment of Patients With Metastatic Her-2 Negative Breast Cancer	Rivoceranib	treatment	2	unknown_status
NCT03166085	PU-H71 With Nab-paclitaxel (Abraxane) in Metastatic Breast Cancer	Paclitaxel Zelavespib	treatment	1	completed
NCT04609215	ImmunoBreast - A Phase Ib Study	No drug interventions	treatment	1 / 2	unknown_status
NCT03322215	HR+/HER2- Advanced Breast Cancer and Endocrine Resistance	Capecitabine Fulvestrant Palbociclib	treatment	2	terminated
NCT02186015	Safety, Feasibility and Efficacy of Vitamin D Supplementation in Women With Metastatic Breast Cancer (SAFE-D)	Cholecalciferol Vitamin D	treatment	2	completed
NCT02607215	Platinum Rechallenge in Patients With Platinum-sensitive mTNBC	Vinorelbine	treatment	2	unknown_status
NCT05266937	Atezolizumab Plus CArboplatin Plus Nab-paclitaxel	Atezolizumab Carboplatin Paclitaxel	treatment	2	active_not_recruiting
NCT05285332	Classified Treatment Strategy for De-novo Metastatic Breast Cancer After Systemic Adjuvant Therapy	No drug interventions	treatment	Not Available	not_yet_recruiting
NCT03002532	Hippocampal-sparing Whole Brain Radiotherapy for Brain Metastases From Breast Cancer	No drug interventions	treatment	Not Available	unknown_status
NCT00454532	A Phase I/II Clinical Trial Assessing Safety and Efficacy of BZL101 for Metastatic Breast Cancer	BZL101	treatment	1 / 2	completed
NCT00715832	A Phase I Cancer Vaccine Study for Patients With Metastatic Breast Cancer	No drug interventions	treatment	1	unknown_status
NCT00924352	Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer	Dasatinib Ixabepilone	treatment	1 / 2	completed
NCT04382352	B002 in Patients With HER2-positive Breast Cancer	No drug interventions	treatment	1	completed
NCT02223052	Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies	Azacitidine	treatment	1	completed
NCT00855452	Activated Allogeneic Lymphocytes for Induction Graft Versus Tumor Effect in Metastatic Solid Tumors	No drug interventions	treatment	2	completed
NCT00694252	Lapatinib and Circulating Tumor Cells in Breast Cancer	Lapatinib	treatment	2	completed
NCT00370552	A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer	Bevacizumab Ixabepilone Paclitaxel	treatment	2	completed
NCT02655952	Dose Escalating Study of Foxy-5 in Breast-, Colon- or Prostate Cancer Patients	Foxy-5	treatment	1	completed
NCT01075100	Ixabepilone + Carboplatin Metastatic Breast Cancer	Carboplatin Ixabepilone	treatment	2	completed
NCT02126800	Rapid Medical Donation Programme for Breast Cancer	No drug interventions	Not Available	Not Available	unknown_status
NCT00354900	Phase I Study of Aprotinin in Advanced Breast Cancer	Aprotinin	treatment	1	terminated
NCT00169000	Safety Study of a New Schedule of Capecitabine and Docetaxel to Treat Cancers	Capecitabine Docetaxel	treatment	1	completed
NCT01862900	Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic Lesions	MEDI-6469	treatment	1	completed
NCT04163159	Genetic Markers of Circulating Tumor DNA for Monitoring Breast Cancer Patients in Costa Rica	No drug interventions	Not Available	Not Available	unknown_status
NCT01589159	A Phase Ⅱ Study of an All-Oral Combination of Low-dose Etoposide/Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and/or Taxanes	Capecitabine Etoposide	treatment	2	completed
NCT01231659	Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer	Everolimus Letrozole	treatment	2	completed
NCT01401959	Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy	Eribulin Trastuzumab	treatment	2	completed
NCT00907959	A Clinical Trial Assessing Safety and Efficacy of BZL101 for Metastatic Breast Cancer	BZL101	treatment	2	unknown_status
NCT02645175	Evaluate the Safety Profile and Ability of TW1025 Oral Solution to Decrease Fatigue	No drug interventions	treatment	2	terminated
NCT01111175	Triple Negative Breast Cancer Biomarker Study	No drug interventions	Not Available	Not Available	completed
NCT06525675	Study to Evaluate the Extended Overall Survival (OS) Data From PARSIFAL Study (The PARSIFAL-LONG Study)	Fulvestrant Letrozole Palbociclib	Not Available	Not Available	active_not_recruiting
NCT04020575	Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)	No drug interventions	treatment	1	recruiting
NCT02257775	Evolution of Resistance to Systemic Therapies in Patients With Breast Cancer	No drug interventions	Not Available	Not Available	terminated
NCT01802970	Safety and Blood Immune Cell Study of Anakinra Plus Physician's Chemotherapy Choice in Metastatic Breast Cancer Patients	Anakinra Capecitabine Eribulin Paclitaxel Vinorelbine	treatment	1	completed
NCT00943670	Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression	Pertuzumab Trastuzumab emtansine	treatment	2	completed
NCT01910870	Phase II Pilot Study Assessing Efficacy of a Cisplatin - Metronomic Cyclophosphamide Treatment in Patients With Metastatic Triple Negative Breast Cancer Resistant to Anthracyclines and Taxanes	Cisplatin Cyclophosphamide	treatment	2	terminated
NCT05143970	A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors	Trastuzumab	treatment	1	recruiting
NCT03950570	ORIN1001 in Patients With Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer	Paclitaxel	treatment	1 / 2	active_not_recruiting
NCT00148070	Phase II Study of Tailored-Dose Docetaxel in Metastatic Breast Cancer	Docetaxel	treatment	2	completed
NCT01007942	Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer	Everolimus Trastuzumab Vinorelbine	treatment	3	completed
NCT04368442	Cohort Study of Patients With HER2-negative MBC and BRCA 1/2 Pathogenic Mutation	No drug interventions	Not Available	Not Available	unknown_status
NCT02536742	Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer	Fulvestrant Palbociclib	treatment	2	completed
NCT04150042	SHARON: A Clinical Trial for Metastatic Cancer With a BRCA or PALB2 Mutation Using Chemotherapy and Patients' Own Stem Cells	Ascorbic acid Carmustine Ethanol Hydroxocobalamin Melphalan	treatment	1	recruiting
NCT05954442	Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype	Everolimus	treatment	3	recruiting
NCT00759642	Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy	Lapatinib	treatment	2	terminated
NCT01847599	Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib	No drug interventions	treatment	Not Available	terminated
NCT00236899	Phase III Study of Two Different Schedules (Weekly and Tri-weekly) of Combination of Gemcitabine and Two Taxanes in MBC	Docetaxel Gemcitabine Paclitaxel	treatment	3	completed
NCT06145399	A Study of 1 8F-FDHT PET/MRIScans in Women With Breast Cancer	No drug interventions	diagnostic	0	withdrawn
NCT01818999	Ixabepilone and SBRT For Metastatic Breast Cancer	Ixabepilone	treatment	2	withdrawn
NCT01512199	Phase 1b/2 Study of U3-1287 in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed Metastatic Breast Cancer (MBC)	Paclitaxel Trastuzumab	treatment	1 / 2	terminated
NCT04924699	A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer	Trastuzumab emtansine Trastuzumab vedotin	treatment	2 / 3	recruiting
NCT05029999	CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer	CDX-301 Doxorubicin	treatment	1	recruiting
NCT04115306	Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer	Fulvestrant	treatment	1 / 2	recruiting
NCT03132506	E-Health Portal for Individualized Treatment Monitoring and Patient Engagement in Oncology Research	No drug interventions	Not Available	Not Available	unknown_status
NCT01315106	High Resolution 3D Diffusion-weighted Breast MRI	No drug interventions	Not Available	Not Available	active_not_recruiting
NCT04240106	Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Breast Cancer (LUZERN)	Niraparib	treatment	2	completed
NCT05043506	European Treatment Patterns and Outcomes Associated With First-Line CDK4/6 Inhibition and Hormonal Therapies	Palbociclib	Not Available	Not Available	completed
NCT04332549	To Assess the Bioavailability and Safety of Paclitaxel Injection Concentrate for Suspension in Subjects With Locally Recurrent or Metastatic Breast Cancer	No drug interventions	treatment	1	withdrawn
NCT01919749	A Pilot Study Utilizing Proteomic and Genomic Profiling for Patients With Metastatic Breast Cancer	No drug interventions	treatment	Not Available	completed
NCT01835236	Trastuzumab & Pertuzumab Followed by T-DM1 in MBC	Paclitaxel Pertuzumab Trastuzumab Trastuzumab emtansine Vinorelbine	treatment	2	completed
NCT02682836	Physical Activity to Maintain Quality of Life and Physical Function in Women With Metastatic Breast Cancer: a Pilot Study	No drug interventions	supportive_care	Not Available	completed
NCT00988936	Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug	No drug interventions	Not Available	2	completed
NCT00574236	Phase II Trial of Bortezomib and Doxorubicin in Metastatic Breast Cancer	Bortezomib Bortezomib D-mannitol Doxorubicin	treatment	2	terminated
NCT01036113	A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer	Firtecan pegol	treatment	2	terminated
NCT01266213	Fulvestrant (F)/Goserelin (G) vs Anastrozole (A)/G vs G for Premenopausal Women	Anastrozole Fulvestrant Goserelin	treatment	2	unknown_status
NCT03492918	Pembrolizumab in Combination With Paclitaxel in the Hormone Receptor-positive Metastatic Breast Cancer With High Tumor Mutational Burden Selected by Whole Exome Sequencing: Korean Cancer Study Group Trial (KCSG BR20-16)	Pembrolizumab	treatment	2	unknown_status
NCT03998618	Telephone Support for Metastatic Breast Cancer Patients	No drug interventions	supportive_care	Not Available	completed
NCT02018419	Increased Frequency of AlloStim(TM) Dosing in Combination With Cryoablation in Metastatic Breast Cancer Patients	No drug interventions	treatment	1 / 2	withdrawn
NCT05833919	Second Line ERIbulin Followed by CApecitabine or the Reverse Sequence in HER2-negative Metastatic Breast Cancer Patients	Capecitabine Eribulin	treatment	2	active_not_recruiting
NCT05455619	Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Women With a PI3K Alteration and HR+/Her2- Breast Cancer	Evexomostat	treatment	1 / 2	recruiting
NCT00555919	ZK 230211 in Postmenopausal Woman With Metastatic Breast Cancer	Lonaprisan	treatment	2	completed
NCT01240941	Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer	Exemestane Goserelin MK-2206	treatment	2	withdrawn
NCT02980341	Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer	No drug interventions	treatment	1 / 2	completed
NCT00632541	A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer	Bevacizumab Sorafenib	treatment	2	terminated
NCT04360941	PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer	Avelumab Palbociclib	other	1	recruiting
NCT05427617	Circulating Tumor DNA (ctDNA)-Guided Late-Line Treatment in Patients With Late-Stage Breast Cancer	Fulvestrant	Not Available	Not Available	completed
NCT04602117	ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer	Paclitaxel Trastuzumab duocarmazine	treatment	1	withdrawn
NCT01421017	Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases	Cyclophosphamide Imiquimod	treatment	1 / 2	completed
NCT00534417	Phase II Trial of Capecitabine With Fulvestrant for Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer	Capecitabine Fulvestrant	treatment	2	completed
NCT03913234	Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients	Letrozole Ribociclib Trastuzumab	treatment	1 / 2	unknown_status
NCT00825734	Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer	Ixabepilone Sorafenib	treatment	1 / 2	completed
NCT00868634	Capecitabine and Bevacizumab ± Vinorelbine in Metastatic Breast Cancer	Bevacizumab Capecitabine Vinorelbine	treatment	3	completed
NCT03161834	Plasma Circulating Tumor DNA Analyses in ER+ Metastatic Breast Cancer	No drug interventions	Not Available	Not Available	withdrawn
NCT03272334	Her2-BATS and Pembrolizumab in Metastatic Breast Cancer	Pembrolizumab	treatment	1 / 2	recruiting
NCT01548534	A Randomised Study of Docosahexaenoic Acid (DHA) in Metastatic Breast Cancer	No drug interventions	supportive_care	3	terminated
NCT04170634	Tumoral Bone Strength Assessment by Numerical Simulation Using Quantitative CT : the MEKANOS Study	No drug interventions	Not Available	Not Available	recruiting
NCT01377324	Molecular Imaging of Fulvestrant Effects on Availability of ER Binding Sites	No drug interventions	diagnostic	2	completed
NCT02073916	T-DM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer	Lapatinib Paclitaxel Trastuzumab emtansine	treatment	1	completed
NCT05716516	STUDY02001740;22SCH740: Estradiol For ER+ Advanced Breast Cancer (ESTHER)	Estradiol	treatment	2	recruiting
NCT03238196	Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer	Erdafitinib Fulvestrant Palbociclib	treatment	1	active_not_recruiting
NCT06428396	Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)	Belzutifan Everolimus Exemestane Fulvestrant	treatment	2	not_yet_recruiting
NCT00570258	Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy	Erlotinib Fulvestrant	treatment	2	terminated
NCT00225758	Lapatinib in Metastatic Breast Cancer Resistant to Hormone Therapy	Lapatinib	treatment	2	terminated
NCT05025735	Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer	Alpelisib Dapagliflozin Fulvestrant	treatment	2	unknown_status
NCT00380835	Study of Amrubicin With or Without Herceptin in Patients With Metastatic Breast Cancer	Amrubicin	treatment	2	withdrawn
NCT01084863	Evaluate Safety, Efficacy and Pharmacokinetics	Paclitaxel Trastuzumab	treatment	1 / 2	completed
NCT04061863	Nivolumab and Eribulin in HER2 Negative Metastatic Breast Cancer	Nivolumab	treatment	1 / 2	unknown_status
NCT01912963	Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer	Eribulin Pertuzumab Trastuzumab	treatment	2	terminated
NCT02649686	Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving Trastuzumab	Durvalumab Trastuzumab	other	1	completed
NCT03473639	A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant Therapy	Capecitabine Entinostat	treatment	1	completed
NCT00661739	A Multicentre Phase I-II Study to Investigate the Combination of Bendamustine With Weekly Paclitaxel as First or Second Line Therapy in Patients With Metastatic Breast Cancer	Bendamustine	treatment	1	completed
NCT02536339	A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy	Pertuzumab Trastuzumab	treatment	2	completed
NCT03997539	A Study of Pyrotinib Plus Vinorelbine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer	Pyrotinib Vinorelbine	treatment	2	unknown_status
NCT02511639	Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer Patients	Anastrozole Everolimus Exemestane Letrozole	treatment	3	completed
NCT02329639	Prospective Study of VEGFR-2 /IL-8 Genetic Interaction in MBC Treated With Paclitaxel and Bevacizumab vs. Chemotherapy	No drug interventions	Not Available	Not Available	unknown_status
NCT02312622	Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer	Etirinotecan pegol Irinotecan	treatment	2	completed
NCT04541225	Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors	No drug interventions	treatment	1	terminated
NCT00065325	The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer	Exemestane Fulvestrant	treatment	3	completed
NCT02792725	Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer	Abemaciclib	Not Available	Not Available	approved_for_marketing
NCT00197925	Dendritic Cell Based Therapy of Metastatic Breast Cancer	No drug interventions	treatment	1 / 2	terminated
NCT00403130	Phase 2 Study of Gemzar, Taxol & Avastin Combination as 1st Line Treatment for Metastatic Breast Cancer	Bevacizumab Gemcitabine Paclitaxel	treatment	2	completed
NCT06507930	The COMPASSION Study	No drug interventions	health_services_research	Not Available	not_yet_recruiting
NCT02479230	Type I-Polarized Autologous Dendritic Cell Vaccine With Tumor Blood Vessel Antigen-Derived Peptides in Metastatic Breast Cancer Patients	Benzalkonium Gemcitabine Sulodexide	treatment	1	completed
NCT02362230	Evaluation of Icotinib in Metastatic Triple-negative Breast Cancer After Second-line Therapy	Icotinib	treatment	2	terminated
NCT01881230	Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)	Carboplatin Gemcitabine Paclitaxel	treatment	2 / 3	completed
NCT02383030	Fulvestrant as Maintenance Therapy After First-line Chemotherapy in HER2 - Postmenopausal MBC Patients	Fulvestrant	diagnostic	3	unknown_status
NCT04188548	A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer	Abemaciclib Alpelisib Everolimus Imlunestrant Pertuzumab Trastuzumab	treatment	1	active_not_recruiting
NCT01550848	A Phase II Study of Abraxane Gemcitabine Combination in Patients With Metastatic Breast Cancer	Gemcitabine Paclitaxel	treatment	2	completed
NCT02505048	A Study to Assess the Efficacy of Rucaparib in Metastatic Breast Cancer Patients With a BRCAness Genomic Signature	Rucaparib	treatment	2	completed
NCT06557148	A Study Comparing Cancer Imaging Approaches in People With Lobular Breast Cancer	No drug interventions	Not Available	Not Available	recruiting
NCT06074757	Open Label, Sequential Dosing , Single Ascending Dose and Multiple Dose Safety Tolerability and Pharmacokinetic Study	Fulvestrant	treatment	1	completed
NCT01056757	Treatment With Ribavirin for Patients With Metastatic Breast Cancer	Ribavirin	treatment	1 / 2	terminated
NCT00522457	Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy	Ertumaxomab	treatment	2	terminated
NCT05753657	A Pilot Study of Monitoring Insulin Levels and Treating Hyperinsulinemia and Hyperglycemia With Pioglitazone in Patients Treated With Alpelisib for Metastatic Breast Cancer.	Pioglitazone	treatment	0	recruiting
NCT05765357	Clinical Study to Compare the Pharmacokinetics and Safety of Trastuzumab for Injection With Herceptin® in Healthy Male Volunteers	Trastuzumab	treatment	1	completed
NCT06533826	TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd	Datopotamab deruxtecan Trastuzumab deruxtecan	treatment	2	not_yet_recruiting
NCT03328026	Combination Study of SV-BR-1-GM With Retifanlimab	Cyclophosphamide Retifanlimab	treatment	1 / 2	enrolling_by_invitation
NCT01543126	IL-6 and IL-8 Level of Blood and Pleural Effusion During Chemotherapy in Metastatic Breast Cancer	No drug interventions	Not Available	Not Available	terminated
NCT00618826	A Study of Biweekly Gemcitabine, Paclitaxel, and Avastin in Patients With Metastatic Breast Cancer	Bevacizumab Gemcitabine Paclitaxel	treatment	2	completed
NCT04140526	Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC	Docetaxel Gotistobart Pembrolizumab	treatment	1 / 2	recruiting
NCT05155566	Treatment Patterns And Clinical Outcomes Among Patients in Latin America Receiving First Line Palbociclib Combinations For HR+/HER2- Advanced/Metastatic Breast Cancer In Real World Settings.	No drug interventions	Not Available	Not Available	completed
NCT00584766	Intensive Combo Chemo With Autologous BM Rescue for Metastatic Breast Cancer	No drug interventions	treatment	2	completed
NCT05693766	Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort	Capecitabine	treatment	2	recruiting
NCT04965766	Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer	No drug interventions	treatment	2	recruiting
NCT06525766	Adaptive Therapy With Capecitabine for the Treatment of Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer	Capecitabine	treatment	2	not_yet_recruiting
NCT00847366	Open Label Trial of Perifosine in Patients Currently Being Treated on Perifosine Trials in Solid Tumors or Multiple Myeloma	Perifosine Tamoxifen Trastuzumab	treatment	Not Available	completed
NCT02738866	Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor	Fulvestrant Palbociclib	treatment	2	active_not_recruiting
NCT04411966	Early Interim 18F-FDG-PET and 18F-FLT-PET for Predicting Treatment Response and Survival in Metastatic Breast Cancer	No drug interventions	diagnostic	Not Available	completed
NCT06321666	Response Evaluation of Cancer Therapeutics in Metastatic Breast Cancer to the Bone	No drug interventions	diagnostic	Not Available	active_not_recruiting
NCT01576666	Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors	Buparlisib Sonidegib	other	1	completed
NCT04941365	Quantifying Systemic Immunosuppression to Personalize Cancer Therapy	No drug interventions	diagnostic	Not Available	withdrawn
NCT03638765	Dendritic Cell Therapy for Brain Metastases From Breast- or Lung Cancer	No drug interventions	treatment	1	unknown_status
NCT00976365	Evaluation of the Safety and Efficacy of THL-P in Metastatic Breast Cancer	No drug interventions	treatment	2	completed
NCT03344965	Olaparib In Metastatic Breast Cancer	Olaparib	treatment	2	active_not_recruiting
NCT03608865	Durvalumab (MEDI4736) and Tremelimumab in Hormone Receptor-positive, Hypermutated Metastatic Breast Cancer Identified by Whole Exome Sequencing	Durvalumab Tremelimumab	treatment	2	completed
NCT03807765	Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain Metastases	Nivolumab	treatment	1	active_not_recruiting
NCT01640665	Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors	Capecitabine Sorafenib	treatment	1	completed
NCT00250874	Myocet, Docetaxel & Trastuzumab as 1st Line Treatment of Patients With HER-2/Neu Positive Metastatic Breast Cancer	Docetaxel Doxorubicin Trastuzumab	treatment	2	unknown_status
NCT05054374	A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer	Fulvestrant Mirdametinib	treatment	1 / 2	completed
NCT01127074	Vaccination of Metastatic Breast Cancer Patients With a CD80-modified Allogeneic Cancer Cell Line (KS2422)	No drug interventions	treatment	1	completed
NCT01797120	Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI	Everolimus Fulvestrant	treatment	2	completed
NCT01784120	A Phase II Trial of Doxorubicin and Genexol-PM in Patients With Advanced Breast Cancer	Doxorubicin	treatment	2	unknown_status
NCT02473120	Study of ESR1 Mutations in Metastatic Breast Cancer	No drug interventions	other	Not Available	completed
NCT04703920	Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer	Belinostat Talazoparib	treatment	1	recruiting
NCT00212082	Gene Expression Profiles in Predicting Chemotherapy Response in Breast Cancer	Docetaxel Doxorubicin	treatment	2	completed
NCT03709082	Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer	Letrozole Palbociclib Trastuzumab emtansine	treatment	1 / 2	terminated
NCT02000882	STAR Cape+BKM120 MBC With Brain Met	Buparlisib Capecitabine Trastuzumab	treatment	2	completed
NCT00394082	ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer	Bevacizumab Paclitaxel	treatment	2	completed
NCT03243331	An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer	Gedatolisib	treatment	1	completed
NCT05227131	Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer	Capecitabine Margetuximab Tucatinib	treatment	2	withdrawn
NCT03685331	HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer	Fulvestrant Olaparib Palbociclib	treatment	1	active_not_recruiting
NCT00788931	A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer	Paclitaxel Panobinostat Trastuzumab	treatment	1	completed
NCT04573231	Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer	Piflufolastat F 18	diagnostic	2	recruiting
NCT01338831	Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer	No drug interventions	treatment	1	completed
NCT03073473	Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers	No drug interventions	Not Available	Not Available	terminated
NCT03456973	Nurse AMIE: A Tablet Based Supportive Care Platform in Metastatic Breast Cancer	No drug interventions	supportive_care	Not Available	completed
NCT04389073	Safety and Efficacy of Toripalimab in HER2- Metastatic Breast Cancer Patients Treated With Metronomic Vinorelbine	Bevacizumab Capecitabine Cisplatin Cyclophosphamide Toripalimab Vinorelbine	treatment	2	unknown_status
NCT00932373	A Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Who Have Previously Received a Trastuzumab-Containing Regimen	Trastuzumab emtansine	treatment	1	completed
NCT01611727	Open-Label,Non-Randomized Trial of Cisplatin Chemotherapy in BRCA1-Positive Metastatic Breast Cancer Patients	Cisplatin	treatment	2	completed
NCT01237327	Multicenter Follow Up Study Of Subjects Who Participated In An Original Protocol Of Exemestane Vs. Megestrol Acetate In Postmenopausal Women With Metastatic Breast Cancer	Exemestane Megestrol acetate	treatment	3	completed
NCT00204776	XELOX for Metastatic Breast Cancer	Capecitabine Oxaliplatin	Not Available	2	completed
NCT03758976	Sweden Cancerome Analysis Network - Breast Recurrence (SCAN-B-rec)	No drug interventions	Not Available	Not Available	recruiting
NCT04293276	Study to Evaluate the Efficacy and Safety of SHR6390 Combined With Pyrotinib in HER2+ Advanced Breast Cancer	Dalpiciclib Pyrotinib	treatment	2	active_not_recruiting
NCT03591276	Phase 1b Study of Pegylated Liposomal Doxorubicin and Pembrolizumab in Endocrine-resistant Breast Cancer	Pembrolizumab	treatment	1 / 2	unknown_status
NCT04937660	Treatment Patterns & Clinical Outcomes of Palbociclib Combinations in HR+HER2-MBC	No drug interventions	Not Available	Not Available	recruiting
NCT01477060	Modulation of Response to Hormonal Therapy With Lapatinib and/or Metformin in Patients With Metastatic Breast Cancer	Lapatinib Metformin	treatment	2	terminated
NCT06180460	CALM: Managing Distress in Malignant Brain Cancer	No drug interventions	supportive_care	Not Available	recruiting
NCT01773460	Everolimus Beyond Progress for Patients Who Had Progress Under Everolimus and Exemestane	Everolimus	treatment	3	terminated
NCT03362060	PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer	Pembrolizumab	treatment	1	active_not_recruiting
NCT05720260	Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC	Capivasertib Durvalumab Fulvestrant Gonadorelin Goserelin	treatment	2	recruiting
NCT02008994	Phase II Study Using Genomic & Proteomic Profiling to Influence Treatments for Patients With Metastatic Breast Cancer	No drug interventions	treatment	2	terminated
NCT00159094	A Trial of Doxil and Multiday Vinorelbine in Patients With Metastatic Breast Cancer	Doxorubicin Vinorelbine	treatment	2	unknown_status
NCT03786094	Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer	Balixafortide Eribulin	treatment	3	terminated
NCT02783794	BP-C1 in Short-term Treatment of Patients With Metastatic Breast Cancer	Platinum	treatment	2	completed
NCT02020291	Phase I Study to Evaluate Safety, Tolerability, Anti-Tumour Activity and PK Profiles of Foxy-5 in Metastatic Breast, Colon or Prostate Cancer	Foxy-5	treatment	1	completed
NCT02719691	Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer	Alisertib Sapanisertib	treatment	1	completed
NCT03732391	Phase 2 Study of Pembrolizumab+Carboplatin in Breast Related Cancer Antigens-related Metastatic Breast Cancer (PEMBRACA)	Carboplatin Pembrolizumab	treatment	2	completed
NCT01439191	Study of Cipterbin®, Used Alone or With Vinorelbine in Patients With HER2/Neu-overexpressed Metastatic Breast Cancer	L-Acetylleucine Vinorelbine	treatment	2	completed
NCT00165880	An Open-label, Randomized, Phase II Study of the Efficacy and Safety of Indisulam (E7070) in Combination With Capecitabine	Indisulam	diagnostic	2	terminated
NCT00134680	Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC	Letrozole Trastuzumab	treatment	2	completed
NCT01928680	Phase II Study of Capecitabine and Cisplatin to Treat Metastatic Triple Negative Breast Cancer	Capecitabine Cisplatin	treatment	2	unknown_status
NCT04597580	Personalised Disease Monitoring in Metastatic Breast Cancer	No drug interventions	Not Available	Not Available	active_not_recruiting
NCT05303129	Prognostic Impact of the Neutrophil/Lymphocyte Ratio (NLR) in the Treatment of First-line Metastatic or Locally Advanced Breast Cancer Treated With CDK4/6 Inhibitor.	No drug interventions	other	Not Available	active_not_recruiting
NCT05629429	Olaparib Maintenance Therapy in Metastatic Breast Cancer	Olaparib	treatment	2	recruiting
NCT02041429	Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca	Paclitaxel Ruxolitinib	treatment	1 / 2	completed
NCT04770129	Real-World Data on Clinical Characteristics, Demographics, and Outcomes of Patients With Metastatic Breast Cancer in Turkey	No drug interventions	Not Available	Not Available	completed
NCT05440929	Evaluation of the Acceptability, Appropriateness, and Feasibility/Usability of a Metastatic Breast-cancer Specific Prognostic Calculator Among Clinicians	No drug interventions	Not Available	Not Available	recruiting
NCT01660529	Multi-peptide Vaccine With Basilixumab for Breast Cancer	CoVac-1	treatment	0	completed
NCT02064829	Bioequivalence Study of IG-001 Versus Nab-paclitaxel in Metastatic or Locally Recurrent Breast Cancer	Albumin human Paclitaxel	treatment	Not Available	completed
NCT02657889	Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer	Niraparib Pembrolizumab	treatment	1 / 2	completed
NCT03644589	Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer	Cisplatin Pembrolizumab	treatment	2	withdrawn
NCT01283789	Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer	Everolimus Lapatinib	treatment	2	unknown_status
NCT04034589	Pyrotinib in Combination With Fulvestrant in Patients With HER2 Positive，HR-Positive Metastatic Breast Cancer	Fulvestrant Pyrotinib	treatment	2	unknown_status
NCT02418689	Poziotinib in Patients With HER2+ Recurrent Stage IV BC Who Have Received at Least 2 Prior HER2-directed Regimens	Poziotinib	treatment	2	completed
NCT04556292	A Phase II Study to Assess the Efficacy and Safety of SC10914 in the Metastatic Breast Cancer Patients	No drug interventions	treatment	2	unknown_status
NCT06320392	Implication of CCR4-NOT Complex Subunit 7 Expression in Natural Killer Cell Resistance in Metastatic Breast Cancer	No drug interventions	Not Available	Not Available	completed
NCT03890744	ModraDoc006/r in Patients With Breast Cancer	Docetaxel	treatment	2	completed
NCT01555944	Prospective Observational Study in Patients With Metastatic Breast Cancer Treated With Anthracyclines	No drug interventions	Not Available	Not Available	completed
NCT05940844	Study of OB-002 in Patients With Refractory Metastatic Cancer	No drug interventions	treatment	1	not_yet_recruiting
NCT06338644	Palbociclib in Metastatic Breast Cancer: Gene Polymorphism-based Study in Egyptian Patients.	Palbociclib	Not Available	Not Available	not_yet_recruiting
NCT05012644	Comparative Real World Tumor Response in Pre-menopausal Metastatic Breast Cancer Patients Treated With Palbociclib + Aromatase Inhibitor or Aromatase Inhibitor Alone	Palbociclib	Not Available	Not Available	completed
NCT03266744	Response Evaluation of Cancer Therapeutics in Metastatic Breast Cancer to the Bone: A Whole Body MRI Study	No drug interventions	other	Not Available	unknown_status
NCT04609540	Pyrotinib Combined With Trastuzumab And Chemotherapy in HER2-positive MBC	Pyrotinib Trastuzumab	Not Available	Not Available	unknown_status
NCT00717340	A Phase 1b/2a, Open-Label, Multi-Center Study of Tivozanib (AV-951) in Combination With Paclitaxel in Subjects With Advanced or Metastatic Breast Cancer	Paclitaxel Tivozanib	treatment	1	completed
NCT00615940	Combination of Oral WX-671 Plus Capecitabine vs. Capecitabine Monotherapy in First-line Her2-negative Metastatic Breast Cancer	Upamostat	treatment	2	completed
NCT00262067	A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1)	Bevacizumab	treatment	3	unknown_status
NCT00192101	Gemcitabine Plus Cisplatin Single Dose Versus Split Dose in the Treatment of Patients With Locally Advanced or Metastatic Breast Cancer After Failure of Anthracyclines and/or Taxanes	Cisplatin Gemcitabine	treatment	2	completed
NCT02649101	Thalidomide Plus Chemotherapy Versus Chemotherapy Alone for Advanced Breast Cancer	Thalidomide	treatment	2	unknown_status
NCT03442504	Prediction of Response to 2nd-line Hormone Therapy by FES CT/PET in Patients With Metastatic Breast Cancer	No drug interventions	other	Not Available	active_not_recruiting
NCT04123704	Sitravatinib in Metastatic Breast Cancer	Sitravatinib	treatment	2	terminated
NCT01045304	Study of SAR240550 (BSI-201) in Combination With Gemcitabine/Carboplatin, in Patients With Metastatic Triple Negative Breast Cancer	Carboplatin Gemcitabine Iniparib	treatment	2	completed
NCT04262804	A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC	Capecitabine Gemcitabine Margetuximab Trastuzumab Vinorelbine	treatment	2	active_not_recruiting
NCT01053104	Dose Adaptation of Capecitabine Using Mobile Phone Toxicity Monitoring	No drug interventions	Not Available	Not Available	completed
NCT00608972	Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer	Bevacizumab Carboplatin Doxorubicin	treatment	2	completed
NCT00251472	A Phase II Trial of Abraxane™ Given Weekly as a Single Agent in First-line Treatment of Metastatic Breast Cancer	Albumin human Paclitaxel	treatment	2	completed
NCT01004172	Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases	Bevacizumab Carboplatin Trastuzumab	treatment	2	completed
NCT00764972	Phase IB/II Trial Combining Vinorelbine With Sorafenib as First-Line Treatment in Patients With Metastatic Breast Cancer	Sorafenib Vinorelbine	treatment	1 / 2	unknown_status
NCT00696072	Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic	Dasatinib Letrozole	treatment	2	completed
NCT06076772	Palbociclib Induced Neutropenia; Risk Factors and Treatment Outcome in Metastatic Breast Cancer Patients	Denosumab Palbociclib	Not Available	Not Available	not_yet_recruiting
NCT02662868	Metastatic Breast Cancer in Brazil: Characterization of Patients and Treatments	No drug interventions	Not Available	Not Available	completed
NCT03637868	Eribulin in Brain Metastases From HER2-negative Breast Cancer	Eribulin	treatment	2	withdrawn
NCT01262469	Evaluating Lapatinib + Capecitabine in Patients Aged 70 and Over With HER2 Metastatic Breast Cancer.	Capecitabine Lapatinib	treatment	2	completed
NCT04251169	Pembrolizumab + Paclitaxel in Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2-negative (HER2-) Non-luminal (by PAM50) Advanced Breast Cancer After Cyclin-dependent Kinase 4/6 (CDK4/6) Inhibitors Progression	Paclitaxel Pembrolizumab	treatment	2	terminated
NCT00706069	Vinorelbine Oral Plus Capecitabine Combination In Metastatic Breast Cancer	Capecitabine Vinorelbine	treatment	1	completed
NCT01116869	China CellSearch Study	No drug interventions	Not Available	Not Available	completed
NCT00191269	Gemcitabine Monotherapy for Metastatic Breast Cancer After Anthracycline and Taxane Regimen	Gemcitabine	treatment	2	completed
NCT00212069	Serum Proteomics to Predict Gemcitabine Sensitivity in Breast Cancer	Carboplatin Gemcitabine	treatment	2	completed
NCT00509769	A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer	Trastuzumab emtansine	treatment	2	completed
NCT01176669	Study of Apatinib in Metastatic Triple-Negative Breast Cancer Patients	Rivoceranib	treatment	2	completed
NCT01501669	Irinotecan/Capecitabine Versus Capecitabine in Patients Treated With A/T for HER2 Negative Metastatic Breast Cancer	Capecitabine Irinotecan	treatment	3	unknown_status
NCT00274469	A Clinical Trial to Compare Efficacy and Tolerability of Faslodex With Arimidex in Patients With Advanced Breast Cancer	Anastrozole Fulvestrant	treatment	2	completed
NCT05033769	Assessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer	Eribulin Paclitaxel	treatment	4	unknown_status
NCT00456846	First Line Therapy for Patients With Metastatic Breast Cancer	Paclitaxel	treatment	2	terminated
NCT02202746	A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer	Lucitanib	treatment	2	terminated
NCT04129346	Technology-Supported Physical Activity Intervention for Metastatic Breast Cancer Survivors: Fit2ThriveMB	No drug interventions	supportive_care	Not Available	completed
NCT02592746	A Study of Palbociclib With Exemestane Plus GnRH Versus Capecitabine in Premenopausal Women With HR+ MBC	Capecitabine Exemestane Gonadorelin Leuprolide Palbociclib	treatment	2	unknown_status
NCT03323346	Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer	Copper Disulfiram	treatment	2	recruiting
NCT02809846	Quell Opioid Reduction and Pain Relief in Patients With Cancer	No drug interventions	supportive_care	Not Available	terminated
NCT00725946	Pilot Study to Determine Radioiodide Accumulation and Dosimetry in Breast Cancers Using 124I PET/CT	Iodine	diagnostic	0	terminated
NCT02175446	Safety and Efficacy Study of Eribulin in Combination With Bevacizumab for Second-line Treatment HER2- MBC Patients	Bevacizumab Eribulin	treatment	2	unknown_status
NCT05759546	PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer	Dalpiciclib Fluzoparib Fulvestrant	treatment	2	recruiting
NCT02144012	A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus the Combination of Trastuzumab Plus Docetaxel in Patients With HER2-positive Breast Cancer	Docetaxel Trastuzumab Trastuzumab emtansine	treatment	3	terminated
NCT03910712	Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC	Anastrozole Exemestane Letrozole Pyrotinib Trastuzumab	treatment	2	unknown_status
NCT06532812	TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer	Cyclophosphamide Fludarabine Human interleukin-2 Pembrolizumab	treatment	1 / 2	recruiting
NCT02072512	The Study of Goserelin Plus Fulvestrant Comparing With Goserelin Plus Anastrozole for Advanced Breast Cancer	Anastrozole Fulvestrant Goserelin	treatment	2	unknown_status
NCT05769010	Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases	Bevacizumab Pyrotinib	treatment	2	recruiting
NCT05301010	Clinical Trial to Assess Efficacy and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients	Docetaxel Trastuzumab	treatment	3	completed
NCT04088110	Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer	Anastrozole Exemestane Letrozole Pyrotinib Trastuzumab	treatment	2	unknown_status
NCT01278810	Phase I Study of Novel Estrogen Receptor(ER) a36 Modifier Icaritin in Advanced Breast Cancer Patients	Icaritin	treatment	1	unknown_status
NCT05217381	Real-World Data of Clinicopathological Characteristics and Management of Breast Cancer Patients According to HER2 Status	No drug interventions	Not Available	Not Available	completed
NCT03321981	MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.	Exemestane Fulvestrant Letrozole Trastuzumab Vinorelbine Zenocutuzumab	treatment	2	completed
NCT06343181	A Qualitative Study on Treatment Adherence in Patients With Metastatic Breast Cancer	No drug interventions	Not Available	Not Available	recruiting
NCT05907681	Prospective Observational Study on Outcome of High-precision Hypo-fractionated Radiotherapy in Metastatic Breast Cancer (PRECISE-M)	No drug interventions	Not Available	Not Available	recruiting
NCT00905281	Study of Impact of Routine "Clinical Cancer Department/Supportive Care Department" Consultation on the Prescription of an Additional Line of Chemotherapy	No drug interventions	supportive_care	Not Available	completed
NCT02284581	Evaluation of Medical Treatments in MBC Patients According Biological Subtype and Line of Treatments	No drug interventions	Not Available	Not Available	recruiting
NCT04963595	Pyrotinib and Vinorelbine Tartrate Capsules With or Without Inetetamab for First Line Treatment in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer	Inetetamab Pyrotinib Vinorelbine	treatment	2	unknown_status
NCT04889495	A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer	Bevacizumab	Not Available	Not Available	not_yet_recruiting
NCT00212095	Docetaxel Combined With Ketoconazole in Treatment of Breast Cancer	Docetaxel Ketoconazole	treatment	2	completed
NCT01423695	Weekly Paclitaxel and Trastuzumab in Metastatic Breast Cancer	Paclitaxel Trastuzumab	treatment	2	completed
NCT00364195	Tesmilifene in Combination With Docetaxel in the Treatment of Metastatic Breast Cancer	Tesmilifene	treatment	2	completed
NCT01837095	Dose Escalation of POL6326 in Combination With Eribulin in Patients With Metastatic Breast Cancer	No drug interventions	treatment	1	completed
NCT02263495	Eribulin Plus Gemcitabine (EG) vs Paclitaxel Plus Gemcitabine (PG) in HER2-Negative Metastatic Breast Cancer	Eribulin Gemcitabine Paclitaxel	treatment	2	completed
NCT05161195	Roll-over Study to Allow Continued Access to Ribociclib	Anastrozole Fulvestrant Goserelin Letrozole Ribociclib Tamoxifen	treatment	4	recruiting
NCT06135714	Metastasis-directed Therapy for Oligometastases of Breast Cancer	No drug interventions	treatment	3	recruiting
NCT03988114	A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer	Abemaciclib	treatment	4	withdrawn
NCT01074814	Pilot Study Using Molecular Profiling to Find Potential Targets & Select Treatments for Pts With Met br ca	No drug interventions	basic_science	0	completed
NCT01433614	Epirubicin and Paclitaxel, Alone or Together With Capecitabine as First Line Treatment in Metastatic Breast Cancer	Capecitabine Epirubicin Paclitaxel	treatment	3	completed
NCT00369655	VEGF Trap in Treating Patients With Metastatic Breast Cancer	Aflibercept	treatment	2	completed
NCT01701050	Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index	No drug interventions	Not Available	Not Available	completed
NCT03427450	Harvest of CTCs From MBC Patients Using the Parsortix™ PC1 System	No drug interventions	Not Available	Not Available	completed
NCT00367250	Safety Study of Combined Immunotherapy With Trastuzumab and Cetuximab in Patients With Metastatic Breast Cancer	Cetuximab Trastuzumab	treatment	1	unknown_status
NCT03878823	Safety and Pharmacokinetics of ODM-209	No drug interventions	treatment	1 / 2	completed
NCT01380808	Capecitabine and Pseudomonas Aeruginosa Combination in Metastatic Breast Cancer (MBC)	Capecitabine Pseudomonas aeruginosa	treatment	2	completed
NCT01027208	A Rollover Study of Ixabepilone (BMS-247550) In Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline	Ixabepilone	treatment	2	completed
NCT04872608	A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer	Letrozole Onapristone Palbociclib	treatment	1	withdrawn
NCT04983238	Evaluation of Safety and Efficacy of Sodium Thiosulfate (BYON5667) Eye Drops to Reduce Ocular Toxicity in Cancer Patients Treated With SYD985	Thiosulfuric acid Trastuzumab duocarmazine	prevention	1 / 2	completed
NCT00912938	Evaluate the Relationship of Bone Remodeling Markers for Skeletal Complications in Metastatic Breast Cancer Patients	Zoledronic acid	diagnostic	4	unknown_status
NCT01656538	A Study of Reolysin For Patients With Advanced/Metastatic Breast Cancer	Paclitaxel Pelareorep	treatment	2	completed
NCT04869943	Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer	Enobosarm Exemestane	treatment	3	terminated
NCT06263543	Sequencing Antibody Drug Conjugates in ER+/HER2 LOW MBC	Sacituzumab govitecan	treatment	2	recruiting
NCT02544243	Vinorelbine/Gemcitabine Versus Vinorelbine/Cisplatin in Metastatic Breast Cancer	Cisplatin Gemcitabine Vinorelbine	treatment	2	unknown_status
NCT05636943	Couples' QOL in Metastatic Breast Cancer	No drug interventions	supportive_care	Not Available	recruiting
NCT03057743	Imaging of in Vivo Sigma-2 Receptor Expression With 18F-ISO-1 Positron Emission Tomography in Metastatic Breast Cancer	No drug interventions	Not Available	Not Available	terminated
NCT05954143	Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer	Pertuzumab	treatment	2	active_not_recruiting
NCT03787303	Study of Euthyroid Hypothyroxinemia in Metastatic Breast Carcinoma	Liothyronine	treatment	2	terminated
NCT01855503	Breast Cancer Molecular Analysis Protocol	No drug interventions	Not Available	Not Available	completed
NCT04659603	Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors	Gemcitabine Tusamitamab ravtansine	treatment	2	active_not_recruiting
NCT02664103	Study of Capecitabine and Cyclophosphamide Administered as a Single Pill in Patients With Advanced Breast Cancer	Capecitabine Cyclophosphamide	treatment	2	completed
NCT03280303	Palbociclib in Real World Practice	No drug interventions	Not Available	Not Available	completed
NCT02423603	PAKT: AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer	Capivasertib Paclitaxel	treatment	2	active_not_recruiting
NCT03854903	WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor	Bosutinib Fulvestrant Palbociclib	treatment	1	active_not_recruiting
NCT00337103	E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes	Capecitabine Eribulin	treatment	3	completed
NCT00051103	Oral Drug Study In Women With Refractory Metastatic Breast Cancer After First-line or Second-line Herceptin.	No drug interventions	treatment	2	completed
NCT02687490	Abraxane in Patients With Visceral Metastases Dominant Metastatic Breast Cancer	Paclitaxel	treatment	2	completed
NCT03642990	NR in Chemo-induced Peripheral Neuropathy	Nicotinamide riboside	treatment	2	terminated
NCT02444390	Molecular Alterations Associated With Resistance to Endocrine Therapy and Impacting Treatment With mTOR Inhibitor	No drug interventions	screening	Not Available	completed
NCT04367090	Pharmacokinetic Study of Pyrotinib and Docetaxel in Combination With Trastuzumab in Patients With HER2 Metastatic Breast Cancer	Docetaxel Pyrotinib Trastuzumab	treatment	1	completed
NCT00567190	A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer	Docetaxel Pertuzumab Trastuzumab	treatment	3	completed
NCT01750164	Patient Derived Breast Cancer Xenografts	No drug interventions	Not Available	Not Available	terminated
NCT03993964	Study to Evaluate the Efficacy and Safety of CDK4/6 Inhibitor SHR6390 Combined With Pyrotinib in the Treatment of HER2-positive Advanced Breast Cancer	Dalpiciclib Pyrotinib	treatment	2	unknown_status
NCT00477464	Lapatinib in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer	Capecitabine Lapatinib	treatment	2	completed
NCT01132664	Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast Cancer	Buparlisib Capecitabine Trastuzumab	treatment	1 / 2	terminated
NCT05826964	Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer	Abemaciclib Alpelisib Anastrozole Capecitabine Elacestrant Eribulin Escitalopram Estradiol Everolimus Exemestane Fulvestrant Letrozole Palbociclib Ribociclib Tamoxifen Vinorelbine	treatment	2	recruiting
NCT02210364	Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC).	Capecitabine Lurbinectedin	treatment	1	completed
NCT00214864	A Study of Weekly Taxotere and Xeloda in Metastatic Breast Cancer	Capecitabine Docetaxel	treatment	2	completed
NCT02310464	Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects	OBI-833	treatment	1	completed
NCT04350021	Effect of Low Dose Metronomic Chemotherapy in Metastatic Breast Cancer	Capecitabine Cyclophosphamide	Not Available	Not Available	completed
NCT04001621	Pyrotinib in Combination With Capecitabine in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer	Capecitabine Pyrotinib	treatment	2	active_not_recruiting
NCT04990921	Study of Palliative Radiation Combined With Pembrolizumab in Unresectable Metastatic Stage IV Breast Cancer	Pembrolizumab	treatment	2	recruiting
NCT00216021	Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer	Capecitabine Oxaliplatin	treatment	2	completed
NCT00905021	Exemestane With Sunitinib (SUTENT®) in Metastatic Breast Cancer	Exemestane Sunitinib	treatment	1 / 2	terminated
NCT01207102	Study Of Abraxane® And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast Cancer	Carboplatin Paclitaxel	treatment	2	terminated
NCT01517802	A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate	Abiraterone Prednisone	treatment	3	completed
NCT02423902	A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer	Ad-RTS-hIL-12 Veledimex	treatment	1 / 2	completed
NCT01935102	Polymorphism Interaction to Predict Bevacizumab Efficacy	No drug interventions	Not Available	Not Available	completed
NCT04246502	Capecitabine Plus Pyrotinib Versus Capecitabine Plus Trastuzumab and Pertuzumab in the First-line Treatment of HER2-positive Metastatic Breast Cancer	Capecitabine Pertuzumab Pyrotinib Trastuzumab	treatment	2	not_yet_recruiting
NCT04212702	ESR1 Mutations in Asian ER+ Metastatic Breast Cancer on Hormonal Therapy-based Treatments	Everolimus	Not Available	Not Available	unknown_status
NCT03328884	Evaluation of the Efficacy and Safety of Nal-IRI for Progressing Brain Metastases in Breast Cancer Patients	Irinotecan	treatment	2	active_not_recruiting
NCT02658084	Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer	Trastuzumab emtansine Vinorelbine	treatment	1 / 2	terminated
NCT04059484	Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer	Anastrozole Exemestane Fulvestrant Letrozole SAR-439459 Tamoxifen	treatment	2	active_not_recruiting
NCT06298084	Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd	Olaparib	treatment	1 / 2	recruiting
NCT00875979	A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab	Pertuzumab Trastuzumab emtansine	treatment	1 / 2	completed
NCT05927779	Study of TFX06 in Women With Advanced Breast Cancer.	No drug interventions	treatment	1 / 2	recruiting
NCT06328387	HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer	Hydroxychloroquine Sacituzumab govitecan Trastuzumab deruxtecan	treatment	1 / 2	recruiting
NCT00248287	PhII ICb With/Without Erbitux in MBC Pts	Carboplatin Cetuximab Irinotecan	treatment	2	active_not_recruiting
NCT05837533	Multicenter Study to Evaluate a Systematized Communication Model for Breast Cancer Patients	No drug interventions	other	Not Available	recruiting
NCT05955833	89Zr-DFO*-Trastuzumab PET in Patients With Gastric or Breast Cancer - a Pilot Study	No drug interventions	diagnostic	1	recruiting
NCT01414933	High Throughput Technologies to Drive Breast Cancer Patients to Specific Phase I/II Trials of Targeted Agents	No drug interventions	Not Available	Not Available	completed
NCT01658033	Bevacizumab Plus Modified FOLFOX6 Regimen as the Salvage Treatment in Metastatic Breast Cancer (MBC) Patients	Bevacizumab Leucovorin Oxaliplatin	treatment	2	completed
NCT00623233	Gemcitabine Plus Bevacizumab in Locally Recurrent or Metastatic Breast Cancer	Bevacizumab Gemcitabine	treatment	2	completed
NCT04432454	Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation	Abemaciclib Lasofoxifene	treatment	2	active_not_recruiting
NCT01876251	A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer	Docetaxel Nirogacestat	treatment	1	terminated
NCT01832051	Clinical Value of 89Zr-trastuzumab PET	Trastuzumab	diagnostic	2	completed
NCT02313051	Everolimus trIal for Advanced prememopausaL Breast Cancer Patients	Everolimus Goserelin Letrozole	treatment	2	unknown_status
NCT02041351	Biweekly Docetaxel in Patients With Metastatic Breast Cancer.	Docetaxel	treatment	2	completed
NCT03139851	Evaluation of Pembrolizumab in Lymphopenic Metastatic Breast Cancer Patients Treated With Metronomic Cyclophosphamide	Cyclophosphamide Pembrolizumab	treatment	2	completed
NCT02404051	Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer	Everolimus Exemestane Fulvestrant	treatment	3	unknown_status
NCT06143553	Paclitaxel Polymeric Micelles for Injection Versus TPC on the Treatment of HER2-negative Metastatic Breast Cancer (MBC).	Albumin human Capecitabine Eribulin Gemcitabine Paclitaxel Vinorelbine	treatment	3	recruiting
NCT04103853	Safety, Tolerability, and Pharmacokinetics of Proxalutamide Therapy in Women With Metastatic Breast Cancer	Proxalutamide	treatment	1	completed
NCT03908853	Pain Phenotyping of Patients With Bone Cancer Pain	No drug interventions	Not Available	Not Available	unknown_status
NCT03555877	Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer	Anastrozole Exemestane Fulvestrant Letrozole Ribociclib	treatment	2	completed
NCT04352777	Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer	Abemaciclib Fulvestrant	treatment	2	active_not_recruiting
NCT00645177	Phase 2 Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone to Treat Metastatic Breast Cancer	Linifanib Paclitaxel	treatment	2	completed
NCT01019577	Clinical Study of Ixabepilone (BMS-247550) by Every-3-week Dosing Regimen in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and Who Are Taxane Resistant	Ixabepilone	treatment	2	completed
NCT01495247	Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer	Dactolisib Paclitaxel	treatment	1 / 2	terminated
NCT03151447	Stereotactic Body Radiation Therapy Combined With Anti-PD-1 Antibody in Metastatic Triple Negative Breast Cancer	No drug interventions	treatment	1	unknown_status
NCT01939847	IMAGE Study: Personalized Molecular Profiling in Cancer Treatment at Johns Hopkins	No drug interventions	treatment	Not Available	completed
NCT00171847	Study of the Efficacy and Safety of Letrozole Combined With Trastuzumab in Patients With Metastatic Breast Cancer	Letrozole Trastuzumab	treatment	4	terminated
NCT01471847	A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to Trastuzumab	Capecitabine Dactolisib Lapatinib Trastuzumab	treatment	1	completed
NCT00333047	Letrozole in Metastatic Breast Cancer in Combination With Chemotherapy	Letrozole	treatment	2 / 3	completed
NCT01528345	Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer	Dovitinib Fulvestrant	treatment	2	terminated
NCT03742245	Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer	Olaparib Vorinostat	treatment	1	recruiting
NCT04263298	Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer	Capecitabine Fulvestrant	treatment	3	recruiting
NCT03409198	Phase IIb Study Evaluating Immunogenic Chemotherapy Combined With Ipilimumab and Nivolumab in Breast Cancer	Cyclophosphamide Doxorubicin Ipilimumab Nivolumab	treatment	2	completed
NCT02802098	Abrogation of Chronic Monoclonal Antibody Treatment-induced T-cell Exhaustion With DURVALUMAB in Advanced HER-2 Negative Breast Cancer	Bevacizumab Durvalumab	basic_science	0	completed
NCT00842998	Efficacy Study of Single Agent Trastuzumab or Lapatinib to Treat HER2-Overexpressing Breast Cancer	Lapatinib Trastuzumab	treatment	2	unknown_status
NCT03424005	A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer	Abemaciclib Atezolizumab Bevacizumab Capecitabine Carboplatin Eribulin Fulvestrant Gemcitabine Inavolisib Ipatasertib Ladiratuzumab vedotin Letrozole Paclitaxel Ribociclib Sacituzumab govitecan Selicrelumab Tocilizumab Trastuzumab deruxtecan	treatment	1 / 2	recruiting
NCT02917005	PalbocIclib in PreMenopausal Women With ER Positive/HER-2 Negative MetAstatic Breast Cancer	Exemestane Goserelin Palbociclib	treatment	2	unknown_status
NCT01259505	Safety Study of Multiple-Vaccine to Treat Metastatic Breast Cancer	No drug interventions	treatment	1	completed
NCT00597597	Phase II Open-Label Trial of Tarceva in Women With Metastatic, Hormone- and HER2-Negative Breast Cancer	Erlotinib	treatment	2	terminated
NCT03669497	Hypo-Fractionated Radiotherapy in Breast Cancer	No drug interventions	treatment	Not Available	completed
NCT04173897	Living Better With Advanced Breast Cancer: Feasibility Evaluation of an Online Supportive Intervention.	No drug interventions	other	Not Available	completed
NCT01975597	Pilot Study of Bone Biopsy and Aspirate in Women With Metastatic Breast Cancer	No drug interventions	Not Available	Not Available	terminated
NCT01351597	A Clinical Trial of Docetaxel and Oxaliplatin in Patients With Recurrent or Metastatic Breast Cancer	Docetaxel Oxaliplatin	treatment	2	unknown_status
NCT01134497	Carboplatin With or Without ZD4054 in Patients With Metastatic Breast Cancer	Carboplatin Zibotentan	treatment	2	withdrawn
NCT05963997	A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer	Elacestrant Samuraciclib	treatment	1 / 2	active_not_recruiting
NCT00281697	A Study to Evaluate the Safety and Efficacy of Bevacizumab in Combination With Chemotherapy in Previously Treated Metastatic Breast Cancer (RIBBON 2)	Bevacizumab	treatment	3	completed
NCT02544997	A Phase II, Single-Arm Trial of Poziotinib as Salvage Treatment in Patients With Metastatic Breast Cancer Who Has HER2 or EGFR Mutation or Activated AR or EGFR Pathway	Poziotinib	treatment	2	completed
NCT03698383	Phase II Study of Herzuma® Plus Gedatolisib in Patients With HER-2 Positive Metastatic Breast Cancer	Gedatolisib Trastuzumab	treatment	2	unknown_status
NCT05660083	Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)	Alpelisib Tilarginine	treatment	2	recruiting
NCT05760183	Discovering Factors in Metastatic Breast Cancer Patients' Clinical Trial Experiences	No drug interventions	Not Available	Not Available	not_yet_recruiting
NCT02491983	Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Advanced Breast Cancer	Fulvestrant Letrozole Palbociclib	treatment	2	completed
NCT05346861	Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab	Pyrotinib Trastuzumab	treatment	3	recruiting
NCT03411161	S 81694 Plus Paclitaxel in Metastatic Breast Cancer	Paclitaxel	treatment	1 / 2	completed
NCT02207361	Paclitaxel in Combination With Carboplatin Versus Paclitaxel Plus Epirubicin in Metastatic Breast Cancer	Carboplatin Epirubicin Paclitaxel	treatment	4	unknown_status
NCT00418028	Standard Versus Continuous Capecitabine in Advanced Breast Cancer	Capecitabine	treatment	2 / 3	completed
NCT04030728	Implementing Patients´ Competence in Oral Breast Cancer Therapy	No drug interventions	Not Available	Not Available	unknown_status
NCT03227328	CDK4/6-inhibitor or Chemotherapy, in Combination With ENDOcrine Therapy, for Advanced Breast Cancer / KENDO	No drug interventions	treatment	2	unknown_status
NCT03275311	Evolution of the Therapeutic Care in Metastatic Breast Cancer From 2008	No drug interventions	Not Available	Not Available	recruiting
NCT01320111	Breast Cancer Study: Paclitaxel Versus Paclitaxel Plus Sorafenib in Second- or Third-line Treatment	Paclitaxel Sorafenib	treatment	2	completed
NCT06214793	Taletrectinib in Previously Treated Metastatic CDH1-mutated Invasive Lobular Cancer (ILC)	taletrectinib	treatment	2	suspended
NCT02538471	LY2157299 Monohydrate (LY2157299) and Radiotherapy in Metastatic Breast Cancer	No drug interventions	treatment	2	terminated
NCT04175171	Clinical Trial of Comparative Study of GB221 Pharmacokinetics	Coprelotamab Trastuzumab	treatment	1	completed
NCT00531271	ABI-008 Trial in Patients With Metastatic Breast Cancer	Docetaxel	treatment	1 / 2	terminated
NCT00958971	Safety and Efficacy of TKI258 in FGFR1 Amplified and Non-amplified Metastatic HER2 Negative Breast Cancer	Dovitinib	treatment	2	completed
NCT05804578	Using a Blood Test to Monitor Metastatic Breast Cancer Treatment	No drug interventions	Not Available	Not Available	recruiting
NCT04834778	A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD)	No drug interventions	treatment	1	completed
NCT00627978	Phase II Study of Ixabepilone in Metastatic Breast Cancer and Its Effects on the Ultrastructure of Neurons	Ixabepilone	treatment	2	completed
NCT03251378	A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors, Colorectal, and Breast Cancer	Fruquintinib	treatment	1	active_not_recruiting
NCT01887288	Capecitabine With Digoxin for Metastatic Breast Cancer	Capecitabine Digoxin	treatment	2	terminated
NCT01349088	Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer	Capecitabine Ixabepilone Motesanib	treatment	1 / 2	withdrawn
NCT01516307	Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects	Adagloxad simolenin Cyclophosphamide	treatment	2	completed
NCT01368107	Study Evaluating Impact of IL-7 on CD4 Lymphopenia, Risks of Severe Haematological Toxicity and Tumor Progression in Metastatic Breast Cancer Patients	No drug interventions	treatment	2	completed
NCT01937507	Hepatic Artery Infusion With FOLFOX in Liver Metastasis From Breast Cancer	No drug interventions	treatment	2	terminated
NCT00707707	Phase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer	Olaparib Paclitaxel	treatment	1	completed
NCT03062007	Open-label Study of Safety, Tolerability and Pharmacokinetics of Multiple Doses of BI-CON-02 in Patients With HER2-positive Metastatic Breast Cancer, Previously Treated With Trastuzumab	No drug interventions	treatment	1	terminated
NCT01941407	First Line Metastatic Breast Cancer Treatment (ESMERALDA)	Bevacizumab Eribulin	treatment	2	completed
NCT01973309	A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer	Paclitaxel Vantictumab	treatment	1	completed
NCT04495309	Metastases-directed Radiotherapy in Addition to Standard Systemic Therapy in Patients With Oligometastatic Breast Cancer	No drug interventions	treatment	Not Available	recruiting
NCT01506609	Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer	Carboplatin Paclitaxel Temozolomide Veliparib	treatment	2	completed
NCT01861509	BP-C1 in Metastatic Breast Cancer Patients	No drug interventions	basic_science	1	completed
NCT00426556	Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer	Everolimus Paclitaxel Trastuzumab	treatment	1	completed
NCT00434356	A Study of Sunitinib in Combination With Bevacizumab and Paclitaxel in Previously Untreated Patients With Metastatic Breast Cancer (SABRE-B)	Bevacizumab Paclitaxel Sunitinib	treatment	2	terminated
NCT02506556	Phosphatidylinositol 3-kinase (PI3K) Alpha iNhibition In Advanced Breast Cancer	Alpelisib	treatment	2	completed
NCT04497285	Real World Study Using Comprehensive Genomic Data on the Next Treatment Decision Making in Metastatic Breast Cancer	No drug interventions	Not Available	Not Available	active_not_recruiting
NCT04031885	A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer	Abemaciclib Capecitabine Docetaxel Fulvestrant Paclitaxel	treatment	4	terminated
NCT04671615	A Study to Understand the Treatment Patterns and Patients and Their Clinical Outcomes Who Are Taking Palbociclib in a Real Life Setting in Israel.	Palbociclib	Not Available	Not Available	completed
NCT00303615	Androgen Therapy for Management of Estrogen/Progesterone Receptor Negative ER(-)PR(-) Metastatic Breast Cancer	Anastrozole Fluoxymesterone	treatment	2	terminated
NCT00735215	Faslodex Registry: Fulvestrant in Current Clinical Practice	No drug interventions	Not Available	Not Available	completed
NCT04571437	Letrozole and Metronomic Capecitabine in ER-positive HER2 Negative Advanced Breast Cancer (B-001 Study)	Capecitabine Letrozole	treatment	2	unknown_status
NCT06018337	A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)	Capecitabine Paclitaxel	treatment	3	recruiting
NCT05283837	A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Immunogenicity of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,)	Pertuzumab	treatment	3	completed
NCT05945732	DESTINY Breast Respond HER2-low Europe	Trastuzumab deruxtecan	Not Available	Not Available	recruiting
NCT02066532	Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer	Ruxolitinib Trastuzumab	treatment	1 / 2	completed
NCT03562832	Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRP	2X-121	treatment	2	active_not_recruiting
NCT01033032	Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer	Amrubicin	treatment	1 / 2	completed
NCT03127332	Metastatic Breast Cancer Treatment Planning	No drug interventions	supportive_care	Not Available	withdrawn
NCT06533332	A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors	No drug interventions	treatment	1	not_yet_recruiting
NCT01957332	IMaging PAtients for Cancer Drug selecTion - Metastatic Breast Cancer	No drug interventions	diagnostic	Not Available	active_not_recruiting
NCT01956552	Changes in Phenotype and Genotype of Breast Cancers During the Metastatic Process and Optimization of Therapeutic Targeting (ESOPE)	No drug interventions	other	Not Available	terminated
NCT02650752	Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases	Capecitabine Lapatinib	treatment	1	completed
NCT06377852	The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study	Palbociclib Ribociclib	treatment	3	not_yet_recruiting
NCT05142800	Screening For BCRL In Targeted Therapy For Breast Cancer	No drug interventions	Not Available	Not Available	recruiting
NCT02624700	2nd Line Treatment With Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer	Pemetrexed Sorafenib	treatment	2	terminated
NCT05021900	Efficacy and Safety of Tenalisib (RP6530), in Patients With Locally Advanced or Metastatic Breast Cancer	Tenalisib	treatment	2	completed
NCT04047459	Investigation of Cancer Cell Extravasation Through mRNA Analysis of Organ-specific Endothelial Cells and Microfluidics	No drug interventions	Not Available	Not Available	completed
NCT05334459	Preoperative Radiotherapy and Systemic Therapy Following Surgery in 'de Novo' Metastatic Breast Cancer	No drug interventions	Not Available	Not Available	recruiting
NCT06081959	Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer	Capecitabine Eribulin Gemcitabine Sacituzumab tirumotecan Vinorelbine	treatment	3	recruiting
NCT00601159	Gemcitabine and Cisplatin as First Line Combination Therapy in Patients With Triple-negative MBC	Cisplatin Gemcitabine	treatment	2	completed
NCT02000375	A Phase II Study Evaluating the Role of Androgen Receptors as Targets for Therapy of Pre-treated Post-menopausal Patients With ER/PgR-negative/AR-positive or ER and/or PgRpositive/ AR-positive Metastatic Breast Cancer (ARTT)	Prasterone	treatment	2	terminated
NCT00912275	Lapatinib in Combination With Oral Vinorelbine for Metastatic Breast Cancer	Lapatinib Vinorelbine	treatment	1 / 2	completed
NCT03455270	G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer	Palbociclib	treatment	1	completed
NCT01113970	Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer	Indibulin	treatment	1 / 2	unknown_status
NCT00313170	A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg	Fulvestrant	treatment	2	completed
NCT00876070	Community Oncology Setting Cost Analysis and Disease Outcomes of Taxane Use in Metastatic Breast Cancer	No drug interventions	Not Available	Not Available	completed
NCT02094742	BIG Molecular Screening Feasibility Study	No drug interventions	screening	Not Available	completed
NCT04296942	BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)	Bintrafusp alfa Entinostat Trastuzumab emtansine	treatment	1	terminated
NCT01306942	Dasatinib In Combination With Trastuzumab And Paclitaxel In First Line Treatment Of Her2-Positive MBC Patients	Dasatinib Paclitaxel Trastuzumab	treatment	1 / 2	completed
NCT04197999	A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer	GMI-1359	treatment	1	terminated
NCT00316199	Efficacy Study of Gemcitabine-Paclitaxel to Treat Metastatic Breast Cancer	Gemcitabine Paclitaxel	treatment	2	completed
NCT02299999	SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer	ABSK-091 Bevacizumab Bicalutamide Capecitabine Capivasertib Cisplatin Cyclophosphamide Docetaxel Doxorubicin Durvalumab Epirubicin Eribulin Gemcitabine Methotrexate Mitomycin Olaparib Paclitaxel Platinum Sapitinib Selumetinib Vandetanib Vinblastine Vincristine Vinorelbine Vistusertib	treatment	2	active_not_recruiting
NCT01334099	Safety Study of Radiation and CP-675,206 Infusion for Breast Cancer Patients	Tremelimumab	treatment	1	terminated
NCT02642406	Therapy Management With Nab-Paclitaxel in Daily Routine	No drug interventions	Not Available	Not Available	unknown_status
NCT04143906	Vinorelbine/Carboplatin Versus Gemcitabine/Carboplatin in Metastatic Breast Cancer	Carboplatin Gemcitabine Vinorelbine	treatment	2	not_yet_recruiting
NCT05759949	First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors	Abemaciclib Fulvestrant Palbociclib Ribociclib	treatment	1	active_not_recruiting
NCT00728949	A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer	Anastrozole Cixutumumab Exemestane Fulvestrant Letrozole Tamoxifen	treatment	2	completed
NCT06151249	Evaluate the Meritup Oral Solution to Decrease Fatigue in Metastatic Breast Cancer Patients Receiving Chemotherapy	No drug interventions	treatment	2	not_yet_recruiting
NCT00288249	Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Breast Cancer	Sagopilone	treatment	2	completed
NCT03591549	Fulvestrant in Metastatic Breast Cancer	Fulvestrant Goserelin	treatment	4	unknown_status
NCT00524849	Zometa and Circulating Vascular Endothelial Growth Factor (VEGF) in Breast Cancer Patients With Bone Metastasis	Zoledronic acid	treatment	2 / 3	completed
NCT01025349	Salvage Therapy With Bevacizumab Plus Docetaxel and Cisplatin for Taiwanese Metastatic Breast Cancer	Bevacizumab Cisplatin Docetaxel	treatment	2	completed
NCT04024436	A Study of TAS-120 in Patients With Metastatic Breast Cancer	Fulvestrant Futibatinib	treatment	2	active_not_recruiting
NCT00764036	Study of Artesunate in Metastatic Breast Cancer	Artesunate	treatment	1	completed
NCT00270413	SU11248 as Consolidation After Response to Taxanes in Metastatic Breast Cancer	Sunitinib	treatment	2	completed
NCT02109913	Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With Exemestane	Everolimus Exemestane	other	Not Available	unknown_status
NCT05340413	Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer.	Olaparib	diagnostic	2	recruiting
NCT02626013	Real-world Evidence Prospective Study on the Effect of Nab-paclitaxel Treatment on the Clinical Outcomes and HRQoL in Patients With MBC in Greece	No drug interventions	Not Available	Not Available	completed
NCT02051218	Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks	Denosumab	supportive_care	3	active_not_recruiting
NCT01939418	Phase Ib/II Trials of RAD001 in Triple Negative Metastatic Breast Cancer	Cisplatin Everolimus Gemcitabine	treatment	1 / 2	terminated
NCT04159818	Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients	Cisplatin Doxorubicin Nivolumab	treatment	2	recruiting
NCT04262518	Feasibility of Integrating the Outcomes4Me Smartphone Navigation Application Into the Care Management of Breast Cancer Patients	No drug interventions	health_services_research	Not Available	unknown_status
NCT00319618	Combination Weekly Taxotere™ With Iressa™ /Placebo in Metastatic Breast Cancer	Docetaxel Gefitinib	treatment	2	completed
NCT04012918	Capecitabine in Combination With Aromatase Inhibitor Versus Aromatase Inhibitors, in Hormonal Receptor Positive Recurrent or Metastatic Breast Cancer Patients, Randomized Controlled Study	Capecitabine	treatment	2	unknown_status
NCT04740918	A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)	Atezolizumab Trastuzumab emtansine	treatment	3	completed
NCT04408118	First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC	Atezolizumab Bevacizumab Paclitaxel	treatment	2	completed
NCT02470819	Genomic and Proteomic Profiling Targets Influenced Treatment in Metastatic Breast Cancer	No drug interventions	treatment	Not Available	withdrawn
NCT03789019	BP-C1 Monotherapy in Patients With Metastatic Breast Cancer Cancer: Estimation of Optimal Duration of Treatment	Platinum	treatment	2	completed
NCT04673019	Nurse AMIE for Echo Show: Randomized Control Trial	No drug interventions	supportive_care	Not Available	completed
NCT06165419	Definitive Radiation for High-Risk Spine Metastases	No drug interventions	treatment	2	recruiting
NCT04857619	Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients With HER2-positive Unresectable or Metastatic Breast Cancer	No drug interventions	Not Available	Not Available	completed
NCT02422641	Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis	Methotrexate	treatment	2	recruiting
NCT05243641	Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test	Capmatinib Neratinib	treatment	1 / 2	recruiting
NCT03755141	Efficacy and Safety of Trastuzumab Biosimilar (Herzuma®) Plus Treatment of Physician's Choice (TPC) in Patients With HER-2 Positive Metastatic Breast Cancer	Trastuzumab	treatment	2	unknown_status
NCT03007641	Improving the Approach to and Management of the Older Metastatic Breast Cancer Patient	No drug interventions	health_services_research	Not Available	completed
NCT05131841	Cipterbin Combined With Vinorelbine in the Treatment of HER2-positive MBC	Vinorelbine	treatment	4	unknown_status
NCT03257917	Understanding Value in Metastatic Breast Cancer	No drug interventions	Not Available	Not Available	completed
NCT04733417	A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer.	Dalpiciclib Famitinib	treatment	2	unknown_status
NCT02650817	Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer	Elacestrant	treatment	1	completed
NCT00634634	Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer	Letrozole Sorafenib	treatment	1 / 2	completed
NCT00349934	IMP321 Plus First-line Paclitaxel in Metastatic Breast Carcinoma	Eftilagimod alfa	treatment	1	completed
NCT03323424	Phase II Trial Assessing the Efficacy of Immuno-Radiation Abscopal Effect in Patients With Metastatic Cancers	No drug interventions	treatment	2	withdrawn
NCT01988324	AR and ER Imaging in Metastatic Breast Cancer	No drug interventions	diagnostic	2	completed
NCT00983424	Cyclosporine A in Combination With Nab-Paclitaxel in Patients With Metastatic Breast Cancer	Cyclosporine Paclitaxel	treatment	1	completed
NCT01108016	Expanding Rural Access: Distance Delivery of Support Groups (Main Study)	No drug interventions	Not Available	3	completed
NCT02608216	[18F]FLT PET/CT in Rb+ Metastatic Breast Cancer	Paclitaxel Ribociclib	diagnostic	1	active_not_recruiting
NCT04092816	Fathers and Mothers Invested in Lives of Their Youth (FAMILY) Study: A Pilot Intervention	No drug interventions	supportive_care	Not Available	terminated
NCT02409316	[18F]FES PET/CT in Endocrine Refractory Breast Cancer	No drug interventions	diagnostic	2	active_not_recruiting
NCT02394496	Overcoming Endocrine Resistance in Metastatic Breast Cancer	Fulvestrant Lapatinib	treatment	3	unknown_status
NCT02555696	Abraxane in Treatment of Metastatic Breast Cancer	Paclitaxel	Not Available	Not Available	completed
NCT03530696	T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer	Palbociclib Trastuzumab emtansine	treatment	2	completed
NCT05233696	Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC	Paclitaxel Pembrolizumab	treatment	2	withdrawn
NCT02580396	Evaluation Of CanADVICE+®M-Health System To Support Breast Cancer Patients Receiving Capecitabine	No drug interventions	other	Not Available	completed
NCT03892096	Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer	No drug interventions	Not Available	Not Available	completed
NCT04509596	DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer	Capecitabine Trastuzumab Trastuzumab emtansine	treatment	1	active_not_recruiting
NCT00525096	Exemestane + Celecoxib vs Exemestane + Placebo in Metastatic Breast Cancer	Celecoxib Exemestane	treatment	3	completed
NCT02000596	1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.	Anastrozole Eribulin Fulvestrant Pertuzumab Trastuzumab	treatment	2	terminated
NCT01498458	Pazopanib in Combination With Capecitabine in Patients With Metastatic Breast Cancer	Capecitabine Pazopanib	treatment	1	completed
NCT05090358	Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer	Alpelisib Canagliflozin Fulvestrant	treatment	2	active_not_recruiting
NCT01658358	ErbB2 Positive Metastatic Breast Cancer	Doxorubicin Lapatinib	treatment	1 / 2	terminated
NCT02730858	Palliative And Oncology Care Model In Breast Cancer	No drug interventions	supportive_care	Not Available	completed
NCT02642458	Pertuzumab in First Line Treatment of HER2-positive Metastatic Breast Cancer Patients	No drug interventions	Not Available	Not Available	unknown_status
NCT01416558	Nab-paclitaxel in Metastatic Breast Cancer Patients Failing Solvent Based Taxane (Tiffany)	Paclitaxel	treatment	2	terminated
NCT01616758	Phase II Study of GTx024 in Women With Metastatic Breast Cancer	Enobosarm	treatment	2	terminated
NCT01942135	Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)	Fulvestrant Palbociclib	treatment	3	completed
NCT03262935	SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer	Capecitabine Eribulin Lapatinib Trastuzumab Trastuzumab duocarmazine Vinorelbine	treatment	3	completed
NCT02207335	Trial of Gemcitabine_Capecitabine Versus Gemcitabine_Carboplatin in Breast Cancer	Capecitabine Carboplatin Gemcitabine	treatment	3	unknown_status
NCT04247035	Τreatment Standards and Outcomes of Patients With ER/PR Positive, HER2-negative Metastatic Breast Cancer	No drug interventions	Not Available	Not Available	unknown_status
NCT05153135	Description of Treatment Patterns and Description and Comparison of Healthcare Resource Utilization and Costs of Women With Metastatic HR+/HER2- Breast Cancer Treated With CDK4/6 Inhibitors	Abemaciclib Palbociclib Ribociclib	Not Available	Not Available	completed
NCT04258735	Genetic Characteristics of Metastatic Breast Cancer Patients	No drug interventions	health_services_research	Not Available	unknown_status
NCT04258163	Association of Survival With Maintenance Therapy in Patients With Metastatic Breast Cancer After First-line Chemotherapy	Anastrozole Capecitabine Doxorubicin Fulvestrant Gemcitabine Letrozole	Not Available	Not Available	completed
NCT04639986	Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)	Capecitabine Eribulin Gemcitabine Sacituzumab govitecan Vinorelbine	treatment	3	active_not_recruiting
NCT01392586	Systemic Therapy With or Without Upfront Surgery in Metastatic Breast Cancer	No drug interventions	treatment	3	terminated
NCT04448886	Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC	Pembrolizumab Sacituzumab govitecan	treatment	2	active_not_recruiting
NCT00508586	PTC299 and Hormonal Agent for Treatment of Metastatic Breast Cancer	PTC299	treatment	1	completed
NCT02605486	Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC)	Bicalutamide Palbociclib	treatment	1 / 2	active_not_recruiting
NCT02474186	Phase II Study for Solid Metastatic Tumors	Capecitabine Docetaxel Paclitaxel	treatment	2	completed
NCT03148886	Advanced Breast Cancer and Lifestyle Exercise Study	No drug interventions	supportive_care	Not Available	completed
NCT02384239	A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer	Fulvestrant Palbociclib Tamoxifen	treatment	2	completed
NCT03901339	Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer	Capecitabine Eribulin Gemcitabine Sacituzumab govitecan Vinorelbine	treatment	3	completed
NCT02626039	Characterization & Comparison of Drugable Mutations in Primary and Metastatic Tumors, CTCs and cfDNA in MBCpatients	No drug interventions	Not Available	Not Available	completed
NCT02581839	Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate	Dexamethasone Eribulin Ondansetron	treatment	2	completed
NCT06308939	Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical Trial	Eribulin Sintilimab	treatment	2	not_yet_recruiting
NCT03955939	A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body	Erbumine Midazolam	treatment	1	completed
NCT06388122	DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Metastatic Breast Cancer Patients	No drug interventions	Not Available	Not Available	recruiting
NCT01626222	4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer	Everolimus Exemestane	treatment	3	completed
NCT04370522	Characterization of Innate Immune System in Patients With Luminal Advanced Breast Cancer	No drug interventions	Not Available	Not Available	active_not_recruiting
NCT03143322	Standard Treatment +/- SBRT in Solid Tumors Patients With Between 1 and 5 Bone-only Metastases	No drug interventions	treatment	Not Available	recruiting
NCT01029925	Dichloroacetate (DCA) in Patients With Previously Treated Metastatic Breast or Non-Small Cell Lung Cancer (NSCL)	Dichloroacetic acid	treatment	2	terminated
NCT01655225	A Study of LY3023414 in Participants With Advanced Cancer	Abemaciclib Cisplatin Fulvestrant LY-3023414 Letrozole Midazolam Pemetrexed	treatment	1	completed
NCT00044525	Evaluation of BAY59-8862 in Taxane-Resistant Metastatic Breast Cancer Patients	Ortataxel	treatment	2	completed
NCT01746225	Schedules of Nab-Paclitaxel in Metastatic Breast Cancer	Paclitaxel	treatment	2	completed
NCT04374825	Optimizing Quality of Life in Women Living With Metastatic Breast Cancer	No drug interventions	supportive_care	Not Available	completed
NCT02563925	Brain Irradiation and Tremelimumab in Metastatic Breast Cancer	Durvalumab Tremelimumab	treatment	Not Available	completed
NCT02864030	PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment	Eribulin	health_services_research	4	completed
NCT00928330	Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy	Pictilisib Trastuzumab Trastuzumab emtansine	treatment	1	completed
NCT05301530	Clinical Trial to Assess Pharmacokinetic Parameters and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients.	Docetaxel Trastuzumab	treatment	1	completed
NCT01323530	A Confirmation Study of Eribulin in Combination With Capecitabine	Capecitabine Eribulin	treatment	1 / 2	completed
NCT02913430	Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib	Fulvestrant Palbociclib Tamoxifen	treatment	0	unknown_status
NCT05758948	Detection of Germline and Somatic Pathogenic Variants in Patients With de Novo Metastatic Breast Cancer	No drug interventions	Not Available	Not Available	active_not_recruiting
NCT00305448	A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg (Plus 250mg Loading Regimen) and 500mg	Fulvestrant	treatment	2	completed
NCT02580448	CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448)	Seviteronel	treatment	1 / 2	completed
NCT04608357	Integrated Patient Avatars for Guiding Systemic Therapy Treatments in Metastatic Breast Cancer Patients	No drug interventions	Not Available	Not Available	unknown_status
NCT05573126	Phase 1/2 Study to Evaluate EP0062 in Patients With Relapsed Locally Advanced or Metastatic Androgen Receptor Positive (AR+)/HER2-/ER+ Breast Cancer	No drug interventions	treatment	1 / 2	recruiting
NCT05331326	A Study of RC48-ADC for the Treatment of HER2-expression Metastatic Breast Cancer With Abnormal Activation of PAM Pathway	No drug interventions	treatment	2	unknown_status
NCT05068726	Clinical Utility of FES F18 PET/CT in Metastatic Breast Cancer Patients	Fluoroestradiol F-18	Not Available	Not Available	terminated
NCT04872166	A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer	No drug interventions	treatment	1	recruiting
NCT01653366	Effect of a Goal Setting Intervention on Exercise in Women With Metastatic Breast Cancer: An Exploration of The Lipogenic Pathway	No drug interventions	treatment	Not Available	terminated
NCT00404066	Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer	Cyclophosphamide Dexamethasone Docetaxel Doxorubicin Filgrastim Lapatinib Pegfilgrastim Trastuzumab	treatment	2	completed
NCT03703466	A Study of Abemaciclib (LY2835219) With and Without Food in Participants With Metastatic Breast Cancer	Abemaciclib	treatment	2	completed
NCT02668666	Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer	Palbociclib Tamoxifen	treatment	2	completed
NCT00496366	Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2/Neu-positive Breast Cancer	Capecitabine Lapatinib	treatment	2	terminated
NCT00496665	ZD6474 (Zactima) and Metronomic Chemotherapy in Advanced Breast Cancer	Cyclophosphamide Methotrexate Vandetanib	treatment	1	completed
NCT02102165	AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer.	No drug interventions	screening	Not Available	recruiting
NCT02315365	Real-World Outcome Research Study on Quality of Life, Work Productivity and Health Care Resource Utilization in Metastatic Breast Cancer	No drug interventions	Not Available	Not Available	completed
NCT00951665	A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer	Paclitaxel Pertuzumab Trastuzumab emtansine	treatment	1 / 2	completed
NCT02001974	Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)	Paclitaxel Reparixin	treatment	1	completed
NCT03026374	Effect of a Mentor-based, Supportive-expressive Program on Survival in Metastatic Breast Cancer	No drug interventions	supportive_care	Not Available	unknown_status
NCT06100874	A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)	Hyaluronidase (human recombinant) Sacituzumab govitecan Trastuzumab	treatment	2	recruiting
NCT05079074	Clinical Application of Circulating Tumor DNA (ctDNA) in Patients With Late-stage Breast Cancer	No drug interventions	Not Available	Not Available	completed
NCT04265274	Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer.	Cisplatin Copper Disulfiram Vinorelbine	treatment	2	withdrawn
NCT00322374	Phase I Combination w/ Epirubicin	Epirubicin Ixabepilone	treatment	1	completed
NCT02966574	Magnetic Resonance Imaging of the Whole Body, Including Diffusion, in the Medical Evaluation of Breast Cancers at High Risk for Metastasis and the Follow-up of Metastatic Cancers	No drug interventions	diagnostic	Not Available	unknown_status
NCT00773474	Lonafarnib in Metastatic Breast Cancer	Lonafarnib	treatment	2	terminated
NCT02939274	An Open Label, Phase II Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin (Visudyne®) for the Treatment of Cutaneous Metastases of Breast Cancer	Verteporfin	treatment	2	unknown_status
NCT00428220	A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.	Sunitinib	treatment	Not Available	completed
NCT02448420	Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer	Palbociclib Trastuzumab Trastuzumab emtansine	treatment	2	completed
NCT06551220	Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer with Different HER2 Expression Patterns	No drug interventions	Not Available	Not Available	recruiting
NCT05563220	Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer	Abemaciclib Alpelisib Capivasertib Elacestrant Everolimus Palbociclib Ribociclib	treatment	1 / 2	recruiting
NCT02790320	Eribulin [Halaven] Use For the Treatment of Advanced Breast Cancer	No drug interventions	Not Available	Not Available	completed
NCT02445482	SOLTI Breast Cancer Molecular Screening Program (AGATA)	No drug interventions	Not Available	Not Available	completed
NCT05486182	Impact of 18F-FES PET on the Therapeutic Treatment of Patients With Metastatic Breast Cancer	No drug interventions	diagnostic	4	recruiting
NCT02424682	Safety of Herceptin/Trastuzumab in Metastatic Breast Cancer	No drug interventions	Not Available	Not Available	completed
NCT04143282	Evaluation of the Effect of Metformin on Metastatic Breast Cancer as Adjuvant Treatment	Metformin	treatment	2	completed
NCT06570031	ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer	Abemaciclib Letrozole Palbociclib	treatment	1	active_not_recruiting
NCT02111031	Clinical Utility of CTC Test in Medicare-Eligible Metastatic Breast Cancer Patients	No drug interventions	Not Available	Not Available	withdrawn
NCT01310231	A Trial of Standard Chemotherapy With Metformin (vs Placebo) in Women With Metastatic Breast Cancer	Metformin	treatment	2	completed
NCT02365831	Observation of Medical Treatments in MBC HER2-negative Patients	No drug interventions	Not Available	Not Available	unknown_status
NCT01282931	Patient-reported Outcome Questionnaire for Women With Metastatic Breast Cancer	No drug interventions	Not Available	Not Available	completed
NCT05086731	Mobile Health to Improve Oral Chemotherapy Adherence Among Women With Breast Cancer	No drug interventions	health_services_research	Not Available	active_not_recruiting
NCT04556773	A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer	Anastrozole Capecitabine Capivasertib Durvalumab Fulvestrant Paclitaxel Trastuzumab deruxtecan	treatment	1	active_not_recruiting
NCT00156273	Determine Feasibility of Quantifying Apoptosis and Bcl-2 Expression in CTCs in Women With Metastatic Breast Cancer	No drug interventions	Not Available	Not Available	completed
NCT00216073	Capecitabine, Oxaliplatin and Trastuzumab in Treating Patients With HER2 Positive Metastatic Breast Cancer	Capecitabine Oxaliplatin Trastuzumab	treatment	2	terminated
NCT05796973	Measuring Oncological Value of Exercise and Statin	Atorvastatin	treatment	3	recruiting
NCT01387373	Intra-hepatic Chemotherapy in Patient With Non-resectable Liver Metastases From Breast Cancer	Capecitabine Oxaliplatin Trastuzumab	treatment	2	completed
NCT00593827	Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer	Ixabepilone	treatment	2	completed
NCT01609127	Tesetaxel Every 3 Weeks vs Weekly vs Capecitabine as 1st-line Therapy for Locally Advanced or Metastatic Breast Cancer	Capecitabine Tesetaxel	treatment	2	unknown_status
NCT00401427	HERVIN: Trastuzumab and Vinorelbine in Metastatic Breast Cancer	Trastuzumab Vinorelbine	treatment	2	completed
NCT01663727	Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer	Bevacizumab Paclitaxel	treatment	3	completed
NCT05933876	The Impact of Radiotherapy on Oligometastatic Cancer	No drug interventions	Not Available	Not Available	recruiting
NCT03636776	Quality of Life and Psychological Vulnerability in Patients With RH+ Metastatic Breast Cancer	No drug interventions	supportive_care	Not Available	terminated
NCT01084876	Demonstrate Efficacy and Safety of Metastatic Breast Cancer	Paclitaxel Trastuzumab	treatment	3	completed
NCT05463276	The Characteristics and Risk Factors of Breast Cancer Patients Trend Distinctive Regional Differences: a Cross-sectional Study	No drug interventions	Not Available	Not Available	completed
NCT01989676	A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02)	Paclitaxel Trastuzumab	treatment	3	completed
NCT01660776	BMS_PD-L1_onco : Assessment of the PD-L1 Protein as a Biomarker in Oncology and Hematology	No drug interventions	Not Available	Not Available	completed
NCT00442260	Doxorubicin HCL Liposome Injection (DOXIL) in Combination With Abraxane in Patients With Metastatic Breast Cancer	Doxorubicin Paclitaxel	treatment	1 / 2	completed
NCT04708860	Feasibility of Fasting & Exercise in Pts With HR+ MBC	No drug interventions	supportive_care	Not Available	completed
NCT05079360	Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer	Escitalopram Estradiol Everolimus Exemestane Veru-111	treatment	2	withdrawn
NCT01633060	A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi	Buparlisib Fulvestrant	treatment	3	terminated
NCT02163694	A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer	Carboplatin Paclitaxel Veliparib	treatment	3	completed
NCT01248494	PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast Cancer	Buparlisib Dactolisib Letrozole	treatment	1	completed
NCT00790894	Trial of Ixabepilone in Patients With HER-2 Negative Metastatic Breast Cancer (HIT)	Ixabepilone	treatment	2	terminated
NCT01307891	Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer	Paclitaxel Tigatuzumab	treatment	2	completed
NCT06459791	Efficacy of Personalized Tumorogram-based Therapy in Cancer Established From Patient-derived Organoid	No drug interventions	treatment	Not Available	not_yet_recruiting
NCT00817362	Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer	Retaspimycin Trastuzumab	treatment	2	terminated
NCT04734262	A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)	Albumin human Paclitaxel Sitravatinib Tislelizumab	treatment	2	active_not_recruiting
NCT01401062	Fresolimumab and Radiotherapy in Metastatic Breast Cancer	Fresolimumab	treatment	2	completed
NCT01300962	Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer	Alpelisib Capecitabine Lapatinib Trastuzumab	treatment	1	completed
NCT02595762	A Study of Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer	No drug interventions	Not Available	Not Available	completed
NCT01451580	Lipo-dox and Cyclophosphamide /5-Fluorouracil in Patients With Metastatic Breast Cancer	No drug interventions	Not Available	2	unknown_status
NCT01989780	Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer	Anastrozole Bevacizumab Exemestane Fulvestrant Goserelin Letrozole Leuprolide Paclitaxel	treatment	2	completed
NCT05176080	Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer	Dalpiciclib Famitinib Fulvestrant	treatment	1 / 2	active_not_recruiting
NCT00307229	Adenovirus Encoding Rat HER-2 in Patients With Metastatic Breast Cancer (AdHER2.1)	No drug interventions	treatment	1	completed
NCT03368729	Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer	Niraparib Trastuzumab	treatment	1 / 2	recruiting
NCT00162929	Her-2/Neu in Patients With Metastatic Breast Cancer (AdHERe)	No drug interventions	treatment	1	completed
NCT01238029	Dose Finding Study for Combination of Capecitabine, Lapatinib and Vinorelbine in Metastatic Breast Cancer	Capecitabine Lapatinib Vinorelbine	treatment	1	terminated
NCT00146029	Companion Pharmacogenetic Study to UMCC 9900/9901	No drug interventions	Not Available	Not Available	terminated
NCT03358589	Molecular Evaluation in Metastatic Breast Cancer	No drug interventions	diagnostic	Not Available	unknown_status
NCT03045289	A Whole-food, Plant-Based Nutrition Intervention in Women With Metastatic Breast Cancer	No drug interventions	treatment	Not Available	completed
NCT01416389	A Study of LY2523355 in Participants With Breast Cancer	Filgrastim Ixabepilone Litronesib Pegfilgrastim	treatment	2	completed
NCT01067989	Low-Dose/Metronomic(LDM)Chemotherapy for Metastatic Breast Cancer	Capecitabine Celecoxib Cyclophosphamide Methotrexate Pamidronic acid Zoledronic acid	treatment	2	terminated
NCT06517992	Collaborative cOMMUNIty Care for Metastatic breAsT cancEr Patients in inDonesia (Communicated)	No drug interventions	supportive_care	Not Available	not_yet_recruiting
NCT01655992	A Trial Comparing S1 Generic With Capecitabine in Metastatic Breast Cancer (MBC)	Capecitabine Gimeracil Oteracil Tegafur	treatment	3	terminated
NCT05735392	Liquid Biopsy: Intercepting Mutational Trajectories of HER2 (Human Epidermal Growth Factor Receptor 2) Breast Cancer (GIM21 Trial)	No drug interventions	other	Not Available	completed
NCT00952692	Study to Assess dHER2+AS15 Cancer Vaccine Given in Combination With Lapatinib to Patients With Metastatic Breast Cancer	Lapatinib SB719125	other	1 / 2	completed
NCT03072992	"Curcumin" in Combination With Chemotherapy in Advanced Breast Cancer	Curcumin Paclitaxel	treatment	2	completed
NCT01935492	8 Continuous vs 8 Intermittent Cycles in First and Second Line in HER2/Neu Neg Metastatic Breast Cancer	Bevacizumab Capecitabine Doxorubicin Paclitaxel	treatment	3	completed
NCT03195192	Utilizing Multiomic Advanced Diagnostics to Identify CDK 4/6 Inhibitor Response Predictors and a Post-treatment Multiomic Signature for Patients With ER+/HER2- Metastatic Breast Cancer	No drug interventions	other	Not Available	completed
NCT03007992	Metronomic Treatment With Daily Oral Vinorelbine as First-line Chemotherapy in Patients With Advanced/Metastatic Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Breast Cancer	Vinorelbine	treatment	2	completed
NCT01288092	BEZ235 Trial in Patients With HER2-(Human Epidermal Growth Factor Receptor 2 Negative) /HR+ (Hormonal Receptor Positive) Metastatic Breast Cancer	Dactolisib	treatment	2	withdrawn
NCT01785992	A Study of the Safety and Effectiveness of Irosustat When Added to an AI in ER+ve Locally Advanced or Metastatic Breast Cancer.	Irosustat	treatment	2	completed
NCT01910844	Phase II Pilot Study Assessing Efficacy of a Cisplatin - Métronomic Cyclophosphamide Treatment in Patients With Stade IV Triple Negative Breast Cancer Secondary Resistant to Anthracyclines and Taxanes	Cisplatin Cyclophosphamide	treatment	2	terminated
NCT00600340	2-arm Trial of Paclitaxel Plus Bevacizumab vs. Capecitabine Plus Bevacizumab	Bevacizumab Capecitabine Paclitaxel	treatment	3	completed
NCT05141240	A Real-world Analysis of Concomitant Medication Use Among Metastatic Breast Cancer Patients Treated With CDK4/6 Inhibitors	Abemaciclib Palbociclib Ribociclib	Not Available	Not Available	completed
NCT00452140	Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer Progressing After Endocrine Treatment	Ertumaxomab	treatment	2	terminated
NCT05544240	Phase 1 Trial of SYNC-T - Immunotherapy for Patients With Advanced/Metastatic Solid Tumors	No drug interventions	treatment	1	recruiting
NCT06383767	A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer	Capecitabine Eribulin Gemcitabine Vinorelbine	treatment	3	recruiting
NCT01256567	A Study of Ramucirumab (IMC-1121B) in Participants With Breast Cancer	Docetaxel Ramucirumab	treatment	1	completed
NCT03970967	Alpha Radiation Emitters Device for the Treatment of Newly Diagnosed Breast Carcinoma Patients With Distant Metastases	No drug interventions	treatment	Not Available	terminated
NCT05463601	Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer	Dalpiciclib Exemestane Fulvestrant Letrozole Mecapegfilgrastim Tamoxifen	prevention	2	recruiting
NCT05567601	Doxil/Caelyx BE Study	Doxorubicin	treatment	1	completed
NCT01492101	The BEACON Study (Breast Cancer Outcomes With NKTR-102)	Etirinotecan pegol	treatment	3	completed
NCT05552001	Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer	Sacituzumab govitecan	treatment	3	recruiting
NCT05132101	Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a First Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South Korea	Palbociclib	Not Available	Not Available	active_not_recruiting
NCT00169104	Effects of Granulocyte Colony-stimulating Factor (G-CSF), Trastuzumab, and Vinorelbine on Immune Cell Function	Filgrastim Trastuzumab Vinorelbine	treatment	2 / 3	terminated
NCT00431704	VinCaT: Vinorelbine, Carboplatin and Trastuzumab in Advanced Her-2 Positive Breast Cancer	Carboplatin Trastuzumab Vinorelbine	treatment	2	active_not_recruiting
NCT03763604	Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer	Abemaciclib	Not Available	Not Available	available
NCT03982004	Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast Cancer	Imiquimod Pembrolizumab	treatment	1	terminated
NCT00894504	Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer	Carboplatin Gemcitabine Panitumumab	treatment	2	completed
NCT05964504	Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)	No drug interventions	Not Available	Not Available	recruiting
NCT01627704	Fluoroestradiol PET Imaging in Predicting Response to Hormone Therapy of Breast Cancer	No drug interventions	treatment	Not Available	completed
NCT02747004	A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer	Abemaciclib Loperamide Tamoxifen	treatment	2	active_not_recruiting
NCT05191004	Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC	Fulvestrant	treatment	1 / 2	withdrawn
NCT05135104	Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period	Palbociclib	Not Available	Not Available	recruiting
NCT00532272	Goserelin/Letrozole in Premenopausal Patients vs Letrozole Alone in Postmenopausal Patients With MBC	Goserelin Letrozole	treatment	2	completed
NCT03051672	Phase II PEMBROLIZUMAB + PALLIATIVE RADIOTHERAPY IN BC	Pembrolizumab	treatment	2	terminated
NCT02436772	Utilization of the OncoCEE™ Platform to Evaluate Selected Biomarker Alterations in CTCs Isolated From Patients With MBC	No drug interventions	Not Available	Not Available	completed
NCT05759572	Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer	Dalpiciclib Fulvestrant Rivoceranib	treatment	2	recruiting
NCT02344472	Detect V / CHEVENDO (Chemo vs. Endo)	Anastrozole Capecitabine Docetaxel Eribulin Exemestane Fulvestrant Goserelin Letrozole Leuprolide Paclitaxel Pertuzumab Ribociclib Trastuzumab Vinorelbine	treatment	3	active_not_recruiting
NCT04276272	D4 Choline Breast PET/CT	No drug interventions	Not Available	Not Available	completed
NCT01161368	A Study Evaluating the Efficacy and Safety of Lapatinib + Vinorelbine in ErbB2 Positive Metastatic Breast Cancer Patients	Lapatinib Vinorelbine	treatment	2	terminated
NCT05892068	A Study of Tucatinib Given Before Surgery to People With HER2+ Cancers That Have Spread to the Brain	Tucatinib	treatment	2	recruiting
NCT04252768	A Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients to Test a New Schedule of Efti (IMP321, Eftilagimod Alpha) as Adjunctive to a Weekly Treatment Regimen of Paclitaxel	Benzalkonium Eftilagimod alfa Paclitaxel	treatment	1	withdrawn
NCT03285568	Patterns of Prescribing and Monitoring of Palbociclib	Palbociclib	Not Available	Not Available	completed
NCT00811369	Trial to Evaluate the Therapeutic Benefit of Fulvestrant in Combination With ZACTIMA in Postmenopausal Women With Bone Predominant, Hormone Receptor Positive Metastatic Breast Cancer	Fulvestrant Vandetanib	treatment	2	completed
NCT04122469	The Role of Stereo-tActic BoDy RadIotherApy iN Oligo-Progressive MalignanT Disease	No drug interventions	treatment	Not Available	recruiting
NCT01526369	A Randomized Study of TH Versus THL in First Line Treatment of HER2-positive Metastatic Breast Cancer	Lapatinib Paclitaxel Trastuzumab	treatment	3	completed
NCT05652569	CATCH: Implementation of Genomics-guided Precision Medicine in Metastatic Breast Cancer	No drug interventions	Not Available	Not Available	recruiting
NCT00241046	Letrozole in the Treatment of 1st and 2nd Line Hormone Receptor Positive Breast Cancer: Pre-therapeutic Risk Assessment	Letrozole	treatment	4	terminated
NCT02863146	Efficacy of the Use of Refrigerant Helmet to Prevent Alopecia in Patients Treated With Eribulin for Breast Cancer	No drug interventions	Not Available	Not Available	terminated
NCT06144346	Metastases Directed Therapy for Oligometastatic Breast Cancer	No drug interventions	treatment	Not Available	recruiting
NCT00490646	A Phase II Combination of Trastuzumab and Ixabepilone Versus Trastuzumab and Docetaxel in Patients With Advanced and/or Metastatic Breast Cancer	Docetaxel Ixabepilone Trastuzumab	treatment	2	completed
NCT04215146	A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study	Avelumab Paclitaxel Pelareorep	treatment	2	active_not_recruiting
NCT00176046	Mistletoe Extract in Early or Advanced Breast Cancer, A Feasibility Study	No drug interventions	treatment	4	completed
NCT06064812	A Phase I Clinical Trial of FWD1802 in Patients With ER+/HER2- BC.	No drug interventions	treatment	1	recruiting
NCT02361112	Study Evaluating Pyrotinib in Combination With Capecitabine In Patients With HER2 Positive Metastatic Breast Cancer	Capecitabine Pyrotinib	treatment	1	completed
NCT00467012	Phase Ⅱ Clinical Study of R435 (Bevacizumab) in Combination With Paclitaxel in Patients With Inoperable Metastatic Breast Cancer	Bevacizumab Paclitaxel	treatment	2	completed
NCT03245112	Halaven Patient Registry (Metastatic Breast Cancer, MBC)	Eribulin	Not Available	Not Available	unknown_status
NCT00691912	Therapy of Metastatic Breast Cancer With Paclitaxel and Liposomal Doxorubicin	Doxorubicin Paclitaxel	treatment	2	terminated
NCT05919212	Trastuzumab Deruxtecan (T-DXd): Tailoring Treatment and Companion Diagnostics (CDx) by Liquid Biopsy	No drug interventions	diagnostic	Not Available	recruiting
NCT06072612	Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.	Cyclophosphamide Retifanlimab	treatment	3	recruiting
NCT01689610	Non-interventional Study With Nab-Paclitaxel (Abraxane®)	No drug interventions	Not Available	Not Available	completed
NCT02051010	ABC Survey - do we Meet the Needs of Patients With Advanced Breast Cancer?	No drug interventions	Not Available	Not Available	completed
NCT01373710	Intrathecal Trastuzumab Administration in Metastatic Breast Cancer Patients Developing Carcinomatous Meningitis	Trastuzumab	treatment	1 / 2	completed
NCT03241810	Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer	Fulvestrant Histidine Seribantumab Sodium chloride	treatment	2	terminated
NCT02651610	Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer	Bavituximab Docetaxel Paclitaxel	treatment	2 / 3	withdrawn
NCT02611310	A Study to Observe Treatment Patterns and Outcomes in Participants in Saudi Arabia With Human Epidermal Growth Factor Receptor 2 (HER2-Positive) Unresectable Locally Advanced or Metastatic Breast Cancer (LA/mBC)	No drug interventions	Not Available	Not Available	terminated
NCT00524810	Liposomal Doxorubicin and Docetaxel in Metastatic Breast Cancer	Docetaxel Doxorubicin	treatment	2	completed
NCT06161181	Enhancing Therapy Adherence Among Metastatic Breast Cancer Patients	No drug interventions	other	Not Available	recruiting
NCT01326481	Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer	Capecitabine Carotuximab	treatment	1 / 2	completed
NCT00807781	Mammaglobin-A DNA Vaccine for Metastatic Breast Cancer	No drug interventions	treatment	1	completed
NCT05900895	Estradiol Plus Olaparib for Breast Cancer (PHOEBE)	Estradiol Olaparib	treatment	1	not_yet_recruiting
NCT06253195	BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors	Fulvestrant Letrozole	treatment	1	recruiting
NCT02753595	Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)	Eribulin Pegvorhyaluronidase alfa	treatment	1 / 2	terminated
NCT00082095	To Compare Treatment With Doxorubicin or Capecitabine for Metastatic Breast Cancer in Women 60 Years and Older	Capecitabine Doxorubicin	treatment	3	terminated
NCT01387295	Intra-hepatic Chemotherapy in Patients With Liver Metastases From Breast Cancer and Limited Extrahepatic Disease	Capecitabine Oxaliplatin Trastuzumab	treatment	2	completed
NCT06450314	Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests.	No drug interventions	treatment	2	not_yet_recruiting
NCT00532714	Phase II Study of Irinotecan/Capecitabine in Patients With Antracycline/Taxane Pretreated MBC	Capecitabine Irinotecan	treatment	2	completed
NCT01060514	Pazopanib + Vinorelbine in Non Small Cell Lung Cancer (NSCLC) and Breast Cancer	Pazopanib Vinorelbine	treatment	1	terminated
NCT00167414	Study for Using Radiosurgery on Limited Metastases of Breast Cancer	No drug interventions	treatment	Not Available	completed
NCT05703555	INTRUSION: Unraveling the INTRatUmoral PK/PD relatION for SAR408701	Tusamitamab ravtansine	treatment	2	withdrawn
NCT01534455	Efficacy and Tolerability of Eribulin Plus Lapatinib in Patients With Metastatic Breast Cancer (E-VITA)	Eribulin Lapatinib	treatment	2	terminated
NCT01715155	Management of Metastatic Breast Cancer in Clinical Practice - Retrospective Study	No drug interventions	Not Available	Not Available	completed
NCT05361655	Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor	Palbociclib	Not Available	Not Available	completed
NCT00265655	Satraplatin for Patients With Metastatic Breast Cancer (MBC)	Satraplatin	treatment	2	completed
NCT05816655	Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer	Fulvestrant Ribociclib	treatment	2	recruiting
NCT02344550	Study of GnRH-A [Leuprorelin(Lorelin Depot] Plus Leterozole +/- Everolimus for Premenopausal Women With Metastatic Breast Cancer	Everolimus Letrozole Leuprolide	treatment	2	completed
NCT01814150	The Association Between Alpha 1 Acid Glycoprotein Level and Outcome Metastatic Cancer Treated With Docetaxel	No drug interventions	Not Available	Not Available	unknown_status
NCT03749850	Image-guided Targeted Doxorubicin Delivery With Hyperthermia to Optimize Loco-regional Control in Breast Cancer	Cyclophosphamide Doxorubicin	treatment	1	unknown_status
NCT01792050	Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer	Docetaxel Indoximod Paclitaxel	treatment	2	completed
NCT04318223	Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy	Palbociclib	treatment	2	unknown_status
NCT06044623	Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients	No drug interventions	treatment	3	recruiting
NCT05577923	Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower)	Dalpiciclib Fulvestrant Pyrotinib Trastuzumab	treatment	2	not_yet_recruiting
NCT03863223	A Study of Pyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast Cancer	Docetaxel Pyrotinib Trastuzumab	treatment	3	active_not_recruiting
NCT00532623	Phase II Study of Gemcitabine/Vinorelbine vs Sequential Gemcitabine Followed by Vinorelbine in Metastatic Breast Cancer	Gemcitabine Vinorelbine	treatment	2	completed
NCT05141708	Treatment Patterns and Clinical Outcomes Among Talazoparib-Treated Adults With HER2-Negative mBC With gBRCA1/2m	Talazoparib	Not Available	Not Available	completed
NCT02829008	Low -Dose-bevacizumab and Pemetrexed Versus TPC in Metastatic HER2-negative Breast Cancer Patients	Bevacizumab Pemetrexed	treatment	2	unknown_status
NCT00303108	Doxil & Carboplatin Plus HER2+ in Metastatic Breast Cancer	Carboplatin Doxorubicin Trastuzumab	treatment	2	completed
NCT04920708	Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression	Abemaciclib Fulvestrant Ipatasertib Palbociclib Ribociclib	treatment	2	recruiting
NCT05534438	A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer	No drug interventions	treatment	2	recruiting
NCT02370238	A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer	Paclitaxel Reparixin	treatment	2	completed
NCT06408038	Are CK+/CD45+ Double-Positive Circulating Cells of Tumor-origin? Characterization in METAstatic Breast Cancer	No drug interventions	other	Not Available	recruiting
NCT06083038	Utilizing Continuous Glucose Monitoring to Characterize and Manage Hyperglycemia in Patients Initiating Alpelisib	Alpelisib	Not Available	Not Available	recruiting
NCT03449238	Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients	Pembrolizumab	treatment	1 / 2	recruiting
NCT01843725	Phase 1 Study Testing the Combination of Aflibercept and Capecitabine in Metastatic Digestive and Breast Cancers	Aflibercept Capecitabine	treatment	1	completed